

THRU ONLINE FILING24th May, 2022

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sir/Madam,

A. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following which were taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai :


- (i) Audited Financial Results (Standalone) for the 4th quarter and financial year ended 31st March, 2022;
- (ii) Report of the Auditors on the Audited Financial Results (Standalone) for the 4th quarter and financial year ended 31st March, 2022;
- (iii) Audited Financial Results (Consolidated) for the 4th quarter and financial year ended 31st March, 2022; and
- (iv) Report of the Auditors on the Audited Financial Results (Consolidated) for the 4th quarter and financial year ended 31st March, 2022.

B. We are also enclosing herewith a declaration stating that the Audit Reports on Standalone and Consolidated Financial Results for the financial year ended 31st March, 2022 are with unmodified opinion.

C. We are also enclosing herewith a press release issued by the Company in respect of its FY 2021-22 Audited Financial Results.

The following are the other items of the businesses which were also approved by the Board :

D. The term of appointment of M/s. G. M. Kapadia & Co., Chartered Accountants is coming to an end at the conclusion of the forthcoming 72nd Annual General Meeting (AGM) of the Company. In their place, the Board has now proposed, subject to the approval of the shareholders, to appoint M/s. Natvarlal Vepari & Co., Chartered Accountants (Firm Registration No. 106971W) as the Statutory Auditors of the Company to carry out the statutory audit activities for a period of 5 (five) years from the conclusion of the 72nd AGM and till the conclusion of the 77th AGM of the Company. The necessary resolution in this regard will be placed before the shareholders for their approval at the ensuing 72nd AGM.



Ipca Laboratories Ltd.
www.ipca.com

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the appointment of new Statutory Auditors:

Proposed appointment of M/s. Natvarlal Vepari & Co., Chartered Accountants (Firm Registration No. 106971W) as the New Statutory Auditors of the Company in place retiring Statutory Auditors		
1.	Reason for Change	Appointment of New Statutory Auditors in place of retiring Statutory Auditors, whose 5 years term of appointment is coming to an end at the ensuing 72 nd AGM of the Company.
2.	Date of appointment & term of appointment	From the conclusion of the ensuing 72 nd AGM and till the conclusion of the 77 th AGM of the Company, which appointment, is subject to the necessary approval of the shareholders.
3.	Brief Profile (in case of appointment)	M/s. Natvarlal Vepari & Co., is a firm of Chartered Accountants which was formed in the year 1959. The firm currently has seven partners and has been engaged, inter-alia, in the statutory audits of different industries for nearly six decades.
4.	Disclosure of relationship with directors	Not related to any Director or Key Managerial Personnel of the Company or their relatives.

- E. The Board has also decided to merge M/s. Tonira Exports Ltd. and M/s. Ramdev Chemical Pvt. Ltd., wholly owned subsidiaries with the Company, subject to necessary approvals. The draft scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013 is attached.

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 :

Proposed merger of M/s. Tonira Exports Ltd. (CIN U51909MH1995PLC248308) and M/s. Ramdev Chemical Pvt. Ltd. (CIN: U24200MH1999PTC120863), unlisted wholly owned subsidiaries, with the Company, subject to necessary approvals			
1.	Name of the Entity (ies) forming part of the amalgamation/merger, details in brief such as size, turnover etc.	Tonira Exports Ltd.	Ramdev Chemical Pvt.Ltd.
Financial year ended 31 st March, 2022 (Rs.lacs)			
	Total Income	2	4852
	Profit/(Loss) after tax	1	(1058)
	Share capital	10	50
	Other equity	14	6050
	Total equity	24	6100
2.	Whether the transaction would fall within related party transaction?	These companies, which are proposed to be merged with the Company, are the Company's wholly owned subsidiaries	



Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837


: 3 :

3.	Areas of business of the entity (ies)	Tonira Exports Ltd. is currently not engaged in any business activities. Ramdev Chemical Pvt. Ltd. is engaged in the manufacturing and marketing of drug intermediates and active pharmaceutical ingredients. The manufacturing facility of this company is situated at Tarapur (Maharashtra).
4.	Rationale for amalgamation/merger	Please refer to Para – Rationale for the scheme in the attached scheme of amalgamation.
5.	In case of cash consideration – Amount or otherwise share exchange ratio	No cash consideration or share exchange ratio is involved in this proposed merger since these companies proposed to be merged are the Company's wholly owned subsidiaries.
6.	Brief details of change in shareholding pattern (if any) of listed entity	No change in the shareholding pattern since the companies proposed to be merged are Company's wholly owned subsidiaries.

Kindly note that the Board Meeting started at 11.30 a.m. and concluded at 1.00 p.m.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Encl : a/a.

Ipca Laboratories Ltd.
www.ipca.com

May 24, 2022

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494


National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time and SEBI Circular No. Cir/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the M/s. G. M. Kapadia & Co., Statutory Auditors of the Company have issued Audit Reports with unmodified opinion on the Audited Financial Statements of the Company (both for Standalone & Consolidated) for the financial year ended 31st March, 2022.


Yours faithfully

For Ipca Laboratories Limited



A. K. Jain
Joint Managing Director /CFO

For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.
www.ipca.com

Ipca Laboratories Limited


Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Sr. No.	Particulars	(₹ Crores)				
		Quarter Ended			Year Ended	
		March 31, 2022 Audited*	December 31, 2021 Unaudited	March 31, 2021 Audited*	March 31, 2022 Audited	March 31, 2021 Audited
I	Revenue from operations	1168.45	1328.47	1040.92	5399.36	5139.16
II	Other Income	14.21	13.24	19.91	56.13	62.24
III	Total Income (I+II)	1182.66	1341.71	1060.83	5455.49	5201.40
IV	Expenses					
	a) Cost of materials consumed	394.69	397.79	409.30	1600.98	1555.53
	b) Purchases of stock-in-trade	91.31	81.80	69.93	282.90	197.68
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(132.75)	(44.06)	(178.15)	(120.76)	(170.73)
	d) Employee benefits expense	272.27	260.08	237.80	1089.63	948.84
	e) Finance costs	3.21	1.27	2.31	7.21	8.14
	f) Depreciation and amortisation expense	52.39	51.25	48.57	204.10	187.72
	g) Other expenses	363.91	321.34	285.40	1303.07	1094.26
	Total Expenses (IV)	1045.03	1069.47	875.16	4367.13	3821.44
V	Profit before exceptional items and tax (III-IV)	137.63	272.24	185.67	1088.36	1379.96
VI	Exceptional items	-	-	-	-	-
VII	Profit before tax (V-VI)	137.63	272.24	185.67	1088.36	1379.96
VIII	Tax Expense					
	-Current tax	30.90	47.62	36.28	197.20	244.98
	-Short / (Excess) provision of earlier years	0.08	-	-	0.08	-
	-Deferred tax liability / (asset)	(3.76)	6.45	(2.09)	20.14	(5.79)
IX	Profit for the period from continuing operations (VII-VIII)	110.41	218.17	151.48	870.94	1140.77
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss -					
	- Actuarial gain/(loss)	1.42	0.37	0.98	1.26	(0.19)
	- Remeasurement of Investment	0.15	-	-	0.15	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.28)	(0.06)	(0.18)	(0.25)	0.03
	B (i) Items that will be reclassified to profit or loss					
	- Exchange difference in translating the financial statement of foreign operation	0.07	(0.31)	(0.18)	(0.54)	(0.36)
	- Gain/(loss) on cash flow hedge	-	0.21	0.14	0.54	0.65
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.01)	0.02	0.01	-	(0.05)
	Other Comprehensive Income / (Loss) for the period net of tax (X)	1.35	0.23	0.77	1.16	0.08
XI	Total Comprehensive Income for the period (IX+X)	111.76	218.40	152.25	872.10	1140.85
XII	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37	25.37
XIII	Other Equity	-	-	-	5497.97	4727.35
XIV	Net Worth	-	-	-	5523.34	4752.72
XV	Earnings per share (of ₹ 1/- each) (Not annualised):					
	Basic (₹)	4.35	8.60	5.97	34.33	45.04
	Diluted (₹)	4.35	8.60	5.97	34.33	45.04



Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2022**

(₹ Crores)			
Sr. No.	Particulars	March 31, 2022 Audited	March 31, 2021 Audited
A	ASSETS :		
1	Non-current assets :		
(a)	Property, Plant and Equipment	2037.05	1824.30
(b)	Capital work-in-progress	285.29	180.85
(c)	Goodwill	7.77	7.77
(d)	Other Intangible assets	19.70	21.08
(e)	Intangible assets under development	3.75	1.15
(f)	Right of use assets	20.26	15.45
(g)	Financial Assets		
	(i) Investments in Subsidiary/Joint Venture/Associate	703.02	474.01
	(ii) Other investments	25.19	-
	(iii) Loans	63.88	81.31
	(iv) Others	68.81	81.83
(h)	Other non-current assets	41.22	44.59
	Total Non current assets	3275.94	2732.34
2	Current assets :		
(a)	Inventories	1750.15	1517.09
(b)	Financial Assets		
	(i) Investments	719.31	393.83
	(ii) Trade receivables	815.94	774.46
	(iii) Cash and cash equivalents	227.80	108.17
	(iv) Bank Balance other than (iii) above	365.17	198.75
	(v) Loans	7.46	19.96
	(vi) Others	131.08	129.02
(c)	Current tax assets (net)	-	-
(d)	Other current assets	163.55	136.51
(e)	Non current assets held for sale	10.46	-
	Total Current assets	4190.92	3277.79
	Total Assets	7466.86	6010.13
B	EQUITY AND LIABILITIES :		
1	Equity :		
(a)	Equity Share Capital	25.37	25.37
(b)	Other Equity	5497.97	4727.35
	Total Equity	5523.34	4752.72
2	Liabilities :		
i	Non-current liabilities :		
(a)	Financial Liabilities		
	(i) Borrowings	395.18	9.13
	(ii) Lease liability	10.93	8.25
	(iii) Other financial liabilities	-	-
(b)	Provisions	40.98	37.29
(c)	Deferred tax liabilities (net)	155.14	135.00
(d)	Other non-current liabilities	1.99	2.15
	Total Non current liabilities	604.22	191.82
ii	Current liabilities :		
(a)	Financial Liabilities		
	(i) Borrowings	365.83	214.07
	(ii) Lease liability	4.47	4.80
	(iii) Trade payables		
	- Dues of micro and small enterprises	72.07	63.65
	- Dues of others	408.34	462.81
	(iv) Other financial liabilities	288.75	151.31
(b)	Current Tax Liabilities (net)	15.77	10.87
(c)	Provisions	100.62	102.28
(d)	Other current liabilities	83.45	55.80
	Total Current liabilities	1339.30	1065.59
	Total Equity and Liabilities	7466.86	6010.13

Note : Figures of the previous period have been regrouped/reclassified wherever necessary, to conform to current period's classification in order to comply with the requirements of amended Schedule III to the Companies Act, 2013 effective April 1, 2021.





Notes:

- 1 The above audited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on May 24, 2022.
- 2 Board has approved merger of M/s. Tonira Exports Ltd. (CIN U51909MH1995PLC248308) and M/s. Ramdev Chemical Pvt. Ltd. (CIN: U24200MH1999PTC120863), unlisted wholly owned subsidiaries, with the Company, subject to necessary approvals, with effect from the appointed date i.e. 1st April, 2022.
- 3 *The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 4 In accordance with IND AS 108 on 'Operating Segments', segment information has been given in the consolidated financial results of the Company, and therefore, no separate disclosure on segment information is given in these standalone financial results.
- 5 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

By Order of the Board
For Ipca Laboratories Limited



A. K. Jain
Joint Managing Director
(DIN 00012657)




Place : Mumbai,
Date : May 24, 2022


Statement of Audited Standalone Cash Flow for the Year ended March 31, 2022

Particulars	2021-22 (₹ Crores)	2020-21 (₹ Crores)
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	1088.36	1379.96
Adjustments for :		
Depreciation, amortisation and impairment expense	204.10	187.72
(Profit) / Loss on sale of Property, plant & equipment	(0.31)	-
Net gain on financial asset through FVTPL	(2.78)	0.53
Property, plant & equipment scrapped/ transferred	11.36	2.86
Sundry balances written off/(back)	(3.17)	(1.48)
Provision for doubtful debts / advances	0.36	0.25
Provision for diminution in value of Investments	39.14	12.68
Bad debts written off	0.76	0.62
Impairment of intangible assets	-	15.84
Unrealised foreign exchange (gain) / loss	(10.20)	(17.13)
Interest income	(33.59)	(37.53)
Interest expense	7.21	8.14
2) Operating profit before working capital changes	212.88	172.50
Decrease / (Increase) in inventories	(233.07)	(250.13)
Decrease / (increase) in Trade Receivables	(29.05)	78.63
Decrease / (increase) in Other Financial assets	(10.14)	(19.10)
Decrease / (increase) in Other assets	(25.45)	(3.19)
Increase / (Decrease) in Trade Payables	(47.72)	71.54
Increase / (Decrease) in Other Financial liabilities	47.29	(12.25)
Increase / (Decrease) in Other liabilities	27.49	(95.58)
Increase / (Decrease) in Provisions	3.28	15.55
3) Cash generated from operation	1033.87	1337.93
Income tax paid (net)	(193.73)	(241.87)
Net cash from operating activities	840.14	1096.06
B. Cash Flow from Investing Activities		
Purchase of Property, plant & equipment including capital Work in progress and intangible assets	(446.01)	(349.65)
Investment in subsidiaries	(57.41)	(28.50)
Investment in Associates	(112.51)	(47.72)
Investment in Joint venture	(98.21)	-
Investment in Others	(25.04)	-
Loan (given)/recovered - Associate	64.48	(34.00)
Loan (given)/recovered - Joint Venture	(4.60)	0.60
Loan (given)/recovered - Subsidiary	(23.50)	(18.00)
Proceeds from Sale of Property, Plant and Equipment	3.18	2.57
Movement in other bank balances	(156.03)	(107.22)
Interest received	31.76	22.36
Net cash from / (used in) Investing activities	(823.89)	(559.56)
C. Cash Flow from Financing Activities		
Issue of Share Capital	-	35.81
Increase / (decrease) in short term borrowings	192.25	(160.44)
Receipt of long term borrowings	413.70	-
Repayment of long-term borrowings	(66.72)	(68.25)
Payment of principal portion of Lease liability	(5.87)	(5.90)
Payment of interest portion of Lease liability	(1.23)	(1.49)
Interest paid	(4.58)	(5.58)
Dividend & dividend tax paid	(101.45)	(101.53)
Net cash from / (used in) financing activities	426.10	(307.38)
Net increase / (decrease) in cash and cash equivalents (A + B + C)	442.35	229.12
Cash and cash equivalents at beginning of year	501.19	272.07
Cash and cash equivalents at end of year	943.54	501.19
Components of cash & cash equivalents :		
Cash and cheques on hand	0.35	0.36
Balance with banks	227.45	107.79
Mutual Funds	719.31	393.83
Less : Fair value (gain) / loss on Mutual funds	(3.57)	(0.79)
	943.54	501.19

By Order of the Board
For Ipca Laboratories Limited

A. K. Jain
Joint Managing Director
(DIN 00012657)



SIGNED FOR IDENTIFICATION
 BY 
G.M. KAPADIA & CO.
MUMBAI.

Place : Mumbai,
Date : May 24, 2022

G. M. KAPADIA & CO.

(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

Independent Auditor's Report on Audit of Annual Standalone Financial Results of Ipca Laboratories Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Ipca Laboratories Limited
Mumbai

Opinion

We have audited the accompanying annual standalone financial results of **Ipca Laboratories Limited** ("the Company") for the year ended March 31, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) is presented in accordance with requirements of Regulation 33 of the Listing Regulations; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2022 and the standalone statement of assets and liabilities and the standalone statement of cash flows as at the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under SAs are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code



of Ethics issued by ICAI. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Director's Responsibilities for the Statement

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of audited standalone financial statements.

The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the standalone statement of assets and liabilities and the standalone statement of cash flows in accordance with the recognition and measurement principles laid down in Ind AS prescribed under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all



relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2022 and March 31, 2021 being the balancing figures between the respective audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subject to limited review by us.

For G. M. Kapadia & Co.

Chartered Accountants

Firm Registration No. 104767W



A handwritten signature in black ink, appearing to read "Atul Shah".

Atul Shah

Partner

Membership No. 039569

UDIN : 22039569AJMIRK3001

Place: Mumbai

Dated this 24th day of May, 2022

Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel: +91 22 6847 4444, E-mail : investors@ipca.com Website : www.ipca.com



STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2022	December 31, 2021	March 31, 2021	March 31, 2022	March 31, 2021
		Audited*	Unaudited	Audited*	Audited	Audited
I	Revenue from operations	1289.10	1430.47	1114.68	5829.79	5419.99
II	Other Income	14.54	12.93	19.92	68.57	62.84
III	Total Income (I+II)	1303.64	1443.40	1134.58	5896.36	5482.83
IV	Expenses :					
	a) Cost of materials consumed	411.51	417.04	417.58	1684.20	1597.14
	b) Purchases of stock-in-trade	142.48	129.17	102.44	480.30	325.95
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(127.78)	(47.66)	(181.41)	(129.65)	(194.79)
	d) Employee benefits expense	297.74	283.88	257.83	1177.39	1013.57
	e) Finance costs	3.38	1.43	1.70	7.69	9.04
	f) Depreciation and amortisation expense	60.94	58.65	52.50	232.42	209.17
	g) Other expenses	345.82	340.43	289.53	1328.29	1133.77
	Total Expenses (IV)	1134.09	1182.74	939.95	4760.64	4093.85
V	Profit from ordinary activity before share of profit / (loss) of associates & joint venture, exceptional items & tax (III - IV)	169.55	260.66	194.63	1135.72	1388.98
VI	Exceptional items	-	-	-	-	-
VII	Profit before tax (V - VI)	169.55	260.66	194.63	1135.72	1388.98
VIII	Tax Expense					
	-Current tax	32.06	50.40	35.72	207.01	248.65
	-Short / (Excess) provision of earlier years	0.50	-	-	0.50	(0.01)
	-Deferred tax liability / (asset)	(3.80)	6.93	(4.79)	17.26	(8.50)
IX	Profit for the period from continuing operations before share of profit / (loss) of associates & joint venture (VII-VIII)	140.79	203.33	163.70	910.95	1148.84
X	Share of Profit / (loss) of associates & joint venture (net of tax) accounted by using the equity method	(8.81)	(4.59)	(2.50)	(21.16)	(7.70)
XI	Profit for the period from continuing operations before non - controlling interest (IX + X)	131.98	198.74	161.20	889.79	1141.14
XII	Less/(Add) : Share of non-controlling interest - profit / (loss)	1.75	1.78	(0.14)	5.71	1.13
XIII	Profit for the period attributable to owners of the Company (XI - XII)	130.23	196.96	161.34	884.08	1140.01
XIV	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss -					
	-Actuarial gain/(loss)	1.38	0.37	1.03	1.22	(0.14)
	-Fair Value change through Other comprehensive income	0.15	-	-	0.15	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.27)	(0.06)	(0.19)	(0.24)	0.02
	B. (i) Items that will be reclassified to profit or loss					
	-Exchange difference in translating the financial statement of foreign operation	0.29	0.42	0.13	1.40	(0.99)
	-Gain/(loss) on cash flow hedge	-	0.21	0.14	0.54	0.65
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.01)	0.02	0.01	-	(0.05)
	C. Share of OCI from investment in associates	(0.04)	(0.01)	0.11	(0.07)	0.11
	Other Comprehensive Income / (Loss) for the period, net of tax	1.50	0.95	1.23	3.00	(0.40)
XV	Total Comprehensive Income for the period (XI + XIV)	133.48	199.69	162.43	892.79	1140.74
	Other Comprehensive Income for the period attributable to :					
	Owners of the parent	1.52	0.95	1.25	2.95	(0.17)
	Non-controlling interest - profit / (loss)	(0.02)	-	(0.02)	0.05	(0.23)
		1.5	0.95	1.23	3.00	(0.40)
	Total Comprehensive Income for the period attributable to :					
	Owners of the parent	131.75	197.91	162.59	887.03	1139.84
	Non-controlling interest - profit / (loss)	1.73	1.78	(0.18)	5.76	0.90
		133.48	199.69	162.43	892.79	1140.74
XVI	Paid-up equity share capital (Face value of ₹ 1/- each)	25.37	25.37	25.37	25.37	25.37
XVII	Other Equity	-	-	-	5466.60	4676.28
XVIII	Net Worth	-	-	-	5491.97	4701.65
XIX	Earning per equity share (of ₹ 1/- each) (Not annualised):					
	Basic (₹)	5.13	7.76	6.36	34.85	45.01
	Diluted (₹)	5.13	7.76	6.36	34.85	45.01



Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837


Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com



STATEMENT OF AUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2022

		(₹ Crores)	
Sr. No.	Particulars	March 31, 2022 Audited	March 31, 2021 Audited
A	ASSETS :		
1	Non-current assets :		
(a)	Property, Plant and Equipment	2187.91	1947.34
(b)	Capital work-in-progress	293.85	183.66
(c)	Goodwill on consolidation	46.39	38.83
(d)	Goodwill on acquisition	7.77	7.77
(e)	Other Intangible assets	154.61	63.04
(f)	Intangible assets under development	12.58	51.16
(g)	Right of use assets	20.84	15.45
(h)	Investment accounted for using the equity method	114.69	77.26
(i)	Financial Assets		
	(i) Investments	155.19	34.17
	(ii) Loans	71.40	81.35
	(iii) Others	69.93	82.42
(j)	Deferred tax assets (net)	2.02	1.95
(k)	Other non-current assets	44.51	47.00
	Total Non-Current Assets	3181.69	2631.40
2	Current assets :		
(a)	Inventories	1857.97	1594.81
(b)	Financial Assets		
	(i) Investments	719.31	393.83
	(ii) Trade receivables	910.78	811.75
	(iii) Cash and cash equivalents	275.19	165.97
	(iv) Bank Balance other than (iii) above	365.47	199.10
	(v) Loans	10.34	1.22
	(vi) Others	131.64	129.44
(c)	Current tax assets (net)	-	-
(d)	Other current assets	176.01	140.84
(e)	Non current assets held for sale	10.46	-
	Total Current Assets	4457.17	3436.96
	Total Assets	7638.86	6068.36
B	EQUITY AND LIABILITIES :		
1	Equity :		
(a)	Equity Share Capital	25.37	25.37
(b)	Other Equity	5466.60	4676.28
	Equity attributable to owners of the Holding Company	5491.97	4701.65
	Non controlling interest	76.92	14.53
	Total Equity	5568.89	4716.18
2	Liabilities :		
I	Non-current liabilities :		
(a)	Financial Liabilities		
	(i) Borrowings	395.18	9.13
	(ii) Lease liability	11.50	8.25
	(iii) Other financial liabilities	0.11	-
(b)	Provisions	42.73	38.56
(c)	Deferred tax liabilities (net)	152.58	133.55
(d)	Other non-current liabilities	1.99	2.15
	Total Non-Current Liabilities	604.09	191.64
II	Current liabilities :		
(a)	Financial Liabilities		
	(i) Borrowings	396.06	243.21
	(ii) Lease liability	4.48	4.80
	(iii) Trade payables :		
	Dues of micro and small enterprises	72.23	64.03
	Dues of others	485.47	600.83
	(iv) Other financial liabilities	301.81	75.90
(b)	Current Tax Liabilities (net)	18.33	11.44
(c)	Provisions	101.52	103.14
(d)	Other current liabilities	85.98	57.19
	Total Current Liabilities	1465.88	1160.54
	Total Equity and Liabilities	7638.86	6068.36

Note : Figures of the previous period have been regrouped/reclassified wherever necessary, to conform to current period's classification in order to comply with the requirements of amended Schedule III to the Companies Act, 2013 effective April 1, 2021.



Notes:

- 1 The above audited consolidated financial statements relates to Ipca Laboratories Ltd. and its Subsidiary Companies, Associates and Joint Venture. The consolidated financial statements have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015
- 2 The above audited consolidated financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on May 24, 2022.
- 3 In accordance with Ind AS-108 "Operating Segments", the operations of the Group are categorised in one segment viz Pharmaceuticals.


The geographic information of the Group's revenues by the Company's country of domicile and other countries is tabulated hereunder:

PARTICULARS	India		Outside India		Total	
	March '22	March '21	March '22	March '21	March '22	March '21
Segment Revenue	3011.18	2,456.93	2818.61	2,963.06	5829.79	5419.99
% of Total Segment Revenue	51.65%	45.33%	48.35%	54.67%	100.00%	100.00%


The geographic information of the Non-current assets "outside India" is less than 10% of the total Non-current assets of the Group and therefore, not disclosed separately.

- 4 *The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 5 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.


By Order of the Board
For Ipca Laboratories Limited



A. K. Jain
Joint Managing Director
(DIN 00012657)



Place : Mumbai
Date : May 24, 2022


SIGNED FOR IDENTIFICATION
BY 
G.M. KAPADIA & CO.
MUMBAI.

Statement of Audited Consolidated Cash Flow for the Year ended March 31, 2022


Particulars	2021-22 (₹ Crores)	2020-21 (₹ Crores)
A. Cash Flow from Operating Activities		
1) Net profit before taxation and extraordinary item	1135.72	1388.98
Adjustments for :		
Depreciation, amortisation and impairment expense	232.42	209.17
Impairment of Intangible Assets	-	15.84
(Profit) / Loss on sale of Property, plant & equipment	0.03	-
Net gain on financial asset through FVTPL	(2.78)	0.53
Property, plant & equipment scrapped / transferred	11.36	2.86
Sundry balances written off / (back)	(3.17)	(1.48)
Provision for doubtful debts / advances	0.36	0.25
Bad debts written off	0.80	0.94
Unrealised foreign exchange (gain) / loss	(9.94)	(17.13)
(Profit)/Loss on Business Combination	(7.37)	-
Interest income	(34.17)	(36.95)
Interest expense	7.57	9.04
2) Operating profit before working capital changes	195.11	183.07
Decrease / (Increase) in Inventories	1330.83	1572.05
Decrease / (Increase) in Trade Receivables	(249.15)	(271.69)
Decrease / (Increase) in Other Financial assets	(80.24)	96.75
Decrease / (Increase) in Other assets	34.75	(18.08)
Increase / (Decrease) in Trade Payables	(33.34)	(5.84)
Increase / (Decrease) in Other Financial liabilities	(109.69)	55.95
Increase / (Decrease) in Other liabilities	135.07	(12.24)
Increase / (Decrease) in Provisions	26.51	(96.81)
3) Cash generated from operation	3.34	15.63
Income tax paid (net)	(272.75)	(236.33)
Net cash from operating activities	1058.08	1335.72
	(202.04)	(245.59)
B. Cash Flow from Investing Activities	856.04	1090.13
Purchase of Property, plant & equipment including Capital work in progress and Intangible assets	(478.95)	(361.55)
Consideration towards Business Combination	(30.11)	-
Investment in Associates	(112.51)	(47.72)
Investment in Joint Venture	(98.21)	-
Investment in Others	(25.04)	-
Loan (given) / recovered - Associates	64.48	(34.00)
Loan (given) / recovered - Joint Venture	(54.60)	0.60
Proceeds from Sale of Property, Plant and Equipment	2.84	2.57
Movement in other bank balances	(155.98)	(102.37)
Interest received	33.03	21.78
Net cash from / (used in) investing activities	(855.05)	(520.69)
C. Cash Flow from Financing Activities		
Issue of Share Capital	-	35.81
Increase / (decrease) in short term borrowings	193.34	(160.37)
Proceeds from long-term borrowings	413.70	2.83
Repayment of long-term borrowings	(66.72)	(68.25)
Payment of principal portion of Lease liability	(5.88)	(5.90)
Payment of interest portion of Lease liability	(1.28)	(1.49)
Interest paid	(4.90)	(6.92)
Dividend & dividend tax paid	(101.45)	(101.53)
Net cash from / (used in) financing activities	426.81	(305.82)
Net increase / (decrease) in cash and cash equivalents (A + B + C)	427.80	263.62
Cash and cash equivalents at beginning of year	559.01	295.39
Movement due to Business combination	4.12	-
Cash and cash equivalents at end of the year	990.93	559.01
Components of cash & cash equivalents :		
Cash and cheques on hand	0.36	0.39
Balance with banks	274.83	165.58
Mutual Funds	719.31	393.83
Less : Fair value (gain) / loss on Mutual funds	(3.57)	(0.79)
	990.93	559.01

By Order of the Board
 For Ipca Laboratories Limited

A. K. Jain
 Joint Managing Director
 (DIN 00012657)



Place : Mumbai
 Date : May 24, 2022

SIGNED FOR IDENTIFICATION
 BY 
G.M. KAPADIA & CO.
MUMBAI.

G. M. KAPADIA & CO.
(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

**Independent Auditor's Report on Audit of Annual Consolidated Financial Results of
Ipca Laboratories Limited pursuant to the Regulation 33 of the Securities and Exchange
Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
The Board of Directors
Ipca Laboratories Limited
Mumbai

Opinion

We have audited the accompanying annual consolidated financial results of **Ipca Laboratories Limited** (hereinafter referred to as "the Holding Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the Group) and its joint venture and associates for the quarter and year ended March 31, 2022 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of other auditors on standalone financial statements and other financial information of subsidiaries, joint venture and associates, the aforesaid statement:

- (i) includes the annual standalone financial results / consolidated financial results, wherever applicable, of the following entities:

Sr. No.	Name of the Entities
	Subsidiaries (Standalone Financial Statements)
1	Ipca Pharma Nigeria Limited, Nigeria
2	Ipca Pharmaceuticals Limited, SA. de CV, Mexico
3	Ipca Laboratories (U.K.) Limited, UK
4	Ipca Pharmaceuticals Inc. USA
5	Ipca Pharma (Australia) Pty Limited, Australia
6	Tonira Exports Limited, India
7	Ramdev Chemicals Private Limited, India
8	Trophic Wellness Private Limited, India (w.e.f. June 11, 2021)
	Step Down Subsidiaries (Standalone Financial Statements)
9	Onyx Scientific Limited, UK
10	Ipca Pharma (NZ) Pty Limited, New Zealand
11	Pisgah Labs Inc., USA
12	Bayshore Pharmaceuticals LLC, USA



Sr. No.	Name of the Entities
	Joint Venture (Standalone Financial Statements)
13	Avik Pharmaceuticals Limited, India
	Associate (Standalone Financial Statements)
14	Krebs Biochemicals Industries Limited, India
	Associate (Consolidated Financial Statements)
15	Lyka Labs Limited, India

- (ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2022 and the consolidated statement of assets and liabilities and the consolidated statement of cash flows as at the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under SAs are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, its joint venture and its associates in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics issued by ICAI. We believe that the audit evidence obtained by us and other auditors in terms of their report referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Director's Responsibilities for the Statement

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of audited consolidated financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group, its joint venture and its associates and the consolidated statement of assets and liabilities and the consolidated statement of cash flows in accordance with the



recognition and measurement principles laid down in Ind AS prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Management and Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and of its joint venture and associates and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Management and Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for assessing the ability of the Group and of its joint venture and associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so. The respective Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for overseeing the financial reporting process of the Group and of its joint venture and associates.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain



audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report the complete set of consolidated financial statements on whether the Group, its joint venture and its associates has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, its joint venture and its associates to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group, its joint venture and its associates to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results and other financial information of the Group, its joint venture and its associates to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding,



among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

- (i) The Statement includes (a) the audited standalone financial results of nine subsidiaries (including six foreign subsidiaries), whose standalone financial statements reflect total assets of Rs. 898.75 crores as at March 31, 2022, total revenue of Rs. 145.85 crores and Rs. 497.20 crores, total net profit of Rs. 9.23 crores and Rs. 16.92 crores, total comprehensive income of Rs. 13.9 crores and Rs. 25.59 crores for the quarter and year ended March 31, 2022, respectively and net cash outflows of Rs. 19.70 crores for the year ended March 31, 2022, as considered in the Statement; and (b) the Group's share of the net profit/(loss) of Rs. (8.83) crores and Rs. (22.75) crores and total comprehensive loss of Rs. (8.87) crores and Rs. (22.82) crores for the quarter and year ended March 31, 2022, respectively, as considered in the preparation of the Statement, in respect two associates and one joint venture. These financial results and other financial information have been audited by their respective independent auditors whose reports have been furnished to us by the Management of the Company and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint venture and associates is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.
- (ii) The Statement also includes the unaudited financial results of three foreign subsidiaries, whose financial statements reflect total assets of Rs. 0.70 crores as at March 31, 2022, total revenue of Rs. 0.01 crores and Rs. 0.08 crores, total net profit of Rs. 0.00 crores and Rs. 0.04 crores, total comprehensive income of Rs. 0.03 crores and Rs. 0.05 crores for the quarter and year ended March 31, 2022, respectively and net cash inflows of Rs. 0.06 crores for the year ended March 31, 2022, as considered in the preparation of the Statement. The financial statements and financial information of these subsidiaries are unaudited and have been certified by the Management. Our opinion on the Statement in so far as it relates to these three subsidiaries is based solely on such management certified unaudited financial statements. In our opinion and according to the information and



explanations given to us by the Management of the Company, these financial statements are not material to the Group.

- (iii) The Management of the Company has also furnished us details of adjustments that are required in case of financial statements of foreign subsidiaries so as to make these financial statements fit for consolidation. Our opinion on the Statement is not modified in respect of above matters with respect to our reliance on the work done and the report of the other auditors and the standalone financial statements and other financial information certified by the Management of the Holding Company.
- (iv) The Statement includes the results for the quarter ended March 31, 2022 and March 31, 2021 being the balancing figure between the respective audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the respective financial year which were subject to limited review by us.

For G. M. Kapadia & Co.

Chartered Accountants

Firm Registration No. 104767W



Atul Shah

Partner

Membership No. 039569

UDIN: 22039569AJMJEN1778

Place: Mumbai

Dated this 24th day of May, 2022

PRESS RELEASE


Ipca Laboratories Q4 FY22/ FY22 Financial Results

Mumbai, May 24, 2022 : Ipca Laboratories Limited today announced its audited financial results for the fourth quarter and financial year ended 31st March, 2022.

Key Financials of Q4 FY22

- Standalone Net total Income up 11% at Rs. 1182.66 crores.
- Consolidated Net total Income up 15% at Rs.1303.64 crores.
- Indian formulations income up 27% at Rs. 551.80 crores.
- Exports Income down 4% at Rs. 527.34 crores.
- Standalone EBITDA margin (before forex (gain)/loss) @ 16.43% in Q4 FY22 as against @21.08% in Q4 FY21.
- Consolidated EBITDA margin @ 18.11% in Q4 FY22 as against @ 20.76% in Q4 FY21.
- Standalone Net Profit at Rs. 110.41 crores down 27%.
- Consolidated Net Profit at Rs. 130.23 crores down 19%.

Standalone Q4 FY22 at a glance			(Rs. Crores)
Particulars	Q4 FY22	Q4 FY21	Growth
Net Total Income	1182.66	1060.83	11%
Export Income	527.34	547.15	-4%
EBITDA before Forex (gain) / loss	194.33	223.61	-13%
Forex (gain) / loss	1.10	(12.94)	-
Finance Cost	3.21	2.31	39%
Depreciation and Amortisation	52.39	48.57	8%
Tax Expense	27.22	34.19	-20%
Net Profit after tax	110.41	151.48	-27%
Earnings per share of Re. 1/- each (Rs.)	4.35	5.97	-27%



Ipca Laboratories Ltd.
www.ipca.com


125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Consolidated Q4 FY22 at a glance			(Rs. Crores)
Particulars	Q4 FY22	Q4 FY21	Growth
Consolidated Net Total Income	1303.64	1134.58	15%
Consolidated EBITDA before Forex (gain) / loss	236.05	235.59	-
Forex (gain) / loss	2.18	(13.24)	-
Finance Cost	3.38	1.70	99%
Depreciation and Amortisation	60.94	52.50	16%
Tax Expense	28.76	30.93	-7%
Profit for the period including share of non – controlling interest but before share of profit / (loss) of associates & joint venture	140.79	163.70	-14%
Share of (profit) / loss of associates & joint venture	8.81	2.50	-
Share of non – controlling interest – (profit) / loss	(1.75)	0.14	-
Consolidated Net Profit after tax	130.23	161.34	-19%
Consolidated Earnings per share of Re. 1/- each (Rs.)	5.13	6.36	-19%

Q4 FY22 Revenue break-up			(Rs. Crores)
Particulars	Q4 FY22	Q4 FY21	Growth
Formulations			
Domestic	551.80	433.61	27%
Exports			
Branded	102.71	101.01	2%
Institutional	79.92	76.22	5%
Generics	163.86	160.77	2%
Total Formulations	898.29	771.61	16%
APIs			
Domestic	76.99	50.79	52%
Exports	180.85	209.15	-14%
Total APIs	257.84	259.94	-1%
Other Operating Income	12.32	9.37	31%
Standalone Revenue from Operations	1168.45	1040.92	12%
Revenue from Operations - Subsidiaries	120.65	73.74	64%
Consolidated Revenue from Operations	1289.10	1114.66	16%
Other Income	14.54	19.92	-27%
Consolidated Net Total Income	1303.64	1134.58	15%



Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Key Financials of FY22

- Standalone Net Total Income up 5% at Rs. 5455.49 crores.
- Consolidated Net Total Income up 8% at Rs. 5896.36 crores.
- Indian formulations income up 27% at Rs. 2508.27 crores.
- Exports Income down 8% at Rs. 2502.69 crores.
- Standalone EBITDA margin (before forex (gain) / loss) @ 23.25% in FY22 as against @29.50% in FY21
- Consolidated EBITDA margin @ 22.81% in FY22 as against @ 28.56% in FY21
- Standalone Net Profit at Rs. 870.94 crores down 24%.
- Consolidated Net Profit at Rs. 884.08 crores down 22%

Standalone FY22 at a glance			(Rs. Crores)
Particulars	FY22	FY21	Growth
Net Total Income	5455.49	5201.40	5%
Export Income	2502.69	2717.19	-8%
EBITDA before Forex (gain) / loss	1268.20	1534.47	-17%
Forex (gain) / loss	(31.47)	(41.35)	-
Finance Cost	7.21	8.14	-11%
Depreciation and Amortisation	204.10	187.72	9%
Tax Expense	217.42	239.19	-9%
Net Profit after tax	870.94	1140.77	-24%
Earnings per share of Re. 1/- each (Rs.)	34.33	45.04	-24%

Consolidated FY22 at a glance			(Rs. Crores)
Particulars	FY22	FY21	Growth
Consolidated Net Total Income	5896.36	5482.83	8%
Consolidated EBITDA before Forex (gain) / loss	1345.04	1565.89	-14%
Forex (gain) / loss	(30.79)	(41.30)	-
Finance Cost	7.69	9.04	-15%
Depreciation and Amortisation	232.42	209.17	11%
Tax Expense	224.77	240.14	-6%
Profit for the period including share of non – controlling interest but before share of profit / (loss) of associates & joint venture	910.95	1148.84	-21%
Share of (profit) / loss of associates & joint venture	21.16	7.70	-
Share of non – controlling interest – (profit) / loss	(5.71)	(1.13)	-
Consolidated Net Profit after tax	884.08	1140.01	-22%
Consolidated Earnings per share of Re. 1/- each (Rs.)	34.85	45.01	-23%



Ipca Laboratories Ltd.
www.ipca.com

325, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837


FY22 Revenue break-up			(Rs. Crores)
Particulars	FY22	FY21	Growth
Formulations			
Domestic	2508.27	1981.67	27%
Exports			
Branded	415.99	403.42	3%
Institutional	318.60	385.35	-17%
Generics	752.15	808.42	-7%
Total Formulations	3995.01	3578.86	12%
APIs			
Domestic	325.42	386.33	-16%
Exports	1015.95	1120.00	-9%
Total APIs	1341.37	1506.33	-11%
Other Operating Income	62.98	53.97	17%
Standalone Revenue from Operations	5399.36	5139.16	5%
Revenue from Operations - Subsidiaries	430.43	280.83	53%
Consolidated Revenue from Operations	5829.79	5419.99	8%
Other Income	66.57	62.84	6%
Consolidated Net Total Income	5896.36	5482.83	8%

About Ipca Laboratories:

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 46 % of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.



A. K. Jain
Joint Managing Director



Encl: Audited Standalone & Consolidated Financial Results

Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at harish.kamath@ipca.com or on +91-22- 6210 6050

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005
 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444
 E: ipca@ipca.com CIN: L24239MH1949PLC007837


**SCHEME OF AMALGAMATION
UNDER SECTIONS 230 TO 232
AND OTHER APPLICABLE PROVISIONS
OF THE COMPANIES ACT, 2013
OF
RAMDEV CHEMICAL PRIVATE LIMITED
("TRANSFEROR COMPANY NO. 1")
AND
TONIRA EXPORTS LIMITED
("TRANSFEROR COMPANY NO. 2")
AND
IPCA LABORATORIES LIMITED
("TRANSFeree COMPANY")
AND
THEIR RESPECTIVE SHAREHOLDERS**

GENERAL

A. Description of Companies and Background:

- I. **RAMDEV CHEMICAL PRIVATE LIMITED**, Transferor Company no 1 (CIN: U24200MH1999PTC120863) is a Private Limited Company incorporated under the Companies Act, 1956 having its registered office at Plot No.142-AB, Kandivli Industrial Estate, Kandivli (West) Mumbai City MH 400067 IN (hereinafter referred to as the ("Transferor Company No. 1"). The Transferor Company is a pharmaceutical company manufacturing in all forms; heavy chemicals of all kinds, (Solid, liquid, gaseous), bulk drugs, medicinal and pharmaceuticals products. The products of the Company are sold in and outside India. The Company has a manufacturing unit in India at Tarapur (Maharashtra) for manufacturing of Active Pharmaceutical Ingredients (Bulk Drugs) (APIs). The 100% share capital of the Company was acquired by Ipca Laboratories Limited and the Company is presently a wholly owned subsidiary of Ipca Laboratories Limited (Transferee Company).
- II. **TONIRA EXPORTS LIMITED**, Transferor Company no 2 (CIN: U51909MH1995PLC248308) is a Private Limited Company incorporated under the Companies Act, 1956 having its registered office at 142AB, Kandivli Industrial Estate Kandivli (West) Mumbai City MH 400067 IN (hereinafter referred to as the "Transferor Company No. 2"). The Transferor Company currently is not engaged in any active business. The Company was the wholly owned subsidiary of Tonira Pharma Ltd. and became wholly owned subsidiary of Ipca laboratories Limited (Transferee Company) upon merger of the said Tonira Pharma Ltd. with Ipca Laboratories Ltd. (Transferee Company)

FOR IPCA LABORATORIES LIMITED


HARGISH P. KAMATH
COMPANY SECRETARY

in April, 2012 and is presently a wholly owned subsidiary of Ipca Laboratories Limited (Transferee Company).

III IPCA LABORATORIES LIMITED, Transferee Company
(CIN:L24239MH1949PLC007837) is a listed public limited company incorporated under the Companies Act, 1913 having its registered office at 48 Kandivli Industrial Estate Kandivli (W) Mumbai, 400067 Maharashtra, India(hereinafter referred to as the “**Transferee Company**”).The Transferee Company was originally incorporated to engage in the business of manufacturing and marketing of drugs and pharmaceuticals, chemicals, cosmetics and toiletries productson October 19, 1949 under the Companies Act, 1913, with the Registrar of Companies, Maharashtra, Mumbai as ‘The Indian Pharmaceutical Combine Association Limited’. The name of the Company was changed to ‘Ipca Laboratories Limited’ and a fresh Certificate of Incorporation consequent on change of name was issued by the Assistant Registrar of Companies, Maharashtra on August 6, 1964. The name of the Company was again changed to ‘Ipca Laboratories Private Limited’ on January 3, 1966 and a fresh Certificate of Incorporation consequent on change of name was issued by the Assistant Registrar of Companies, Maharashtra. The status of the Company was later changed to deemed public company by deleting “private” from its name pursuant to Section 43A(1-A) of the Companies Act, 1956 by the Assistant Registrar of Companies, Maharashtra, on August 9, 1988. Vide Certificate of Change of Name issued by the Additional Registrar of Companies, Maharashtra, Mumbai on January 7, 1994, the status of the Company was changed from “deemed public Company” to “full fledged public Company”. The Equity Shares of the Company are listed on BSE and NSE

The Transferor Company 1 &2 are wholly owned subsidiary of the Transferee Company as the 100% of issued, subscribed and paid-up share capital of the Transferor Company 1 & 2 is held by the Transferee Company as on the date of this Scheme. The Transferee Company’s equity shares are listed on the BSE Limited and National Stock Exchange India Limited.

IV. This Scheme of Amalgamation provides for the amalgamation of the Transferor Company1 & 2 with the Transferee Company and other consequential matters pursuant to Sections 230 to 232 and other relevant provisions of the Companies Act, 2013.

B. Rationale for the Scheme

The Transferee Company is holding 100% equity stake in the Transferor Company 1 &2. In order to consolidate and effectively manage the Transferor Company 1 &2 and the Transferee Company in a single entity and to achieve, *inter-alia*, economies of scale and efficiency, the merger is being undertaken. The amalgamation of the Transferor Company 1&2 with the Transferee Company would *inter alia* have the following benefits:

- (a) Amalgamation to be value accretive to the shareholders of the Transferee Company as the shareholders would have direct access to the core business of the Transferor Company 1&2;
- (b) Greater integration and greater financial strength and flexibility for the amalgamated entity, which would result in maximising overall shareholder value;
- (c) Greater efficiency in cash management of the Transferee Company and unfettered access to cash flow generated by the combined business which can be deployed more efficiently to fund organic and inorganic growth opportunities, to maximize shareholder value;
- (d) Improved organizational capability and leadership, arising from the pooling of human capital having diverse skills, talent and vast experience to compete successfully in an increasingly competitive industry;
- (e) Cost savings are expected to flow from more focused operational efforts, rationalization, standardisation and simplification of business processes, and the elimination of duplication, and rationalization of administrative expenses;
- (f) Reduction in the multiplicity of legal and regulatory compliances required at present to be separately carried out by the Transferor Companies and the Transferee Company;
- (g) To optimally leverage the larger assets base and cash flow of the amalgamated entity; and
- (h) Amalgamation will result in the Transferee Company directly controlling and managing the business of the Transferor Companies which would lead to simplification of the shareholding structure and reduction of shareholding tiers.

In view of the aforesaid, the Board of Directors of the Transferor Companies and the Transferee Company have considered and proposed the amalgamation of the entire undertaking and business of the Transferor Companies with the Transferee Company in order to benefit the stakeholders of all the companies. Accordingly, the Board of Directors of the Transferor Companies and the Transferee Company have formulated this Scheme of Amalgamation for the transfer and vesting of the entire undertaking and business of the Transferor Companies with and into the Transferee Company pursuant to the provisions of Section 230 to Section 232 and other relevant provisions of the Companies Act, 2013.

- C. Under the Scheme, there is no arrangement with the creditors, either secured or unsecured of the Transferor and/or the Transferee Company. No compromise is offered under the

Scheme to any of the creditors of the Transferor Companies and/or the Transferee Company. The liability of the creditors of the Transferor Companies and/or the Transferee Company, under the Scheme, is neither being reduced nor being extinguished.

D. Parts of the Scheme:

This Scheme of Amalgamation is divided into the following parts:

- (i) **Part I** deals with definitions of the terms used in this Scheme of Amalgamation and sets out the share capital of the Transferor Companies and the Transferee Company;
- (ii) **Part II** deals with the transfer and vesting of the Undertaking (as hereinafter defined) of the Transferor Companies to and in the Transferee Company;
- (iii) **Part III** deals with the issue of new equity shares by the Transferee Company to the eligible shareholders of the Transferor Companies, as applicable;
- (iv) **Part IV** deals with the accounting treatment for the amalgamation in the books of the Transferee Company and dividends; and
- (v) **Part V** deals with the dissolution of the Transferor Companies and the general terms and conditions applicable to this Scheme of Amalgamation and other matters consequential and integrally connected thereto.

PART I
DEFINITIONS AND SHARE CAPITAL

1. DEFINITIONS

In this Scheme, unless repugnant to the meaning or context thereof, the following expressions shall have the following meaning:

- 1.1. "**Act**" means the Indian Companies Act, 1913, the Companies Act, 1956, Companies Act, 2013, the rules and regulations made thereunder and will include any statutory re-enactment or amendment(s) thereto, from time to time;
- 1.2. "**Accounting Standards**" means the Indian Accounting Standards as notified under Section 133 of the 2013 Act, as amended from time to time, issued by the Ministry of Corporate Affairs and the other accounting principles generally accepted in India;
- 1.3. "**Applicable Laws**" means any statute, law, regulation, ordinance, rule, regulation, judgment, order, decree, clearance, approval, terms of any approval, permit or no-objection of any Governmental Authority, directive, guideline, policy, requirement, listing agreement or other governmental restriction or any similar form of decision, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental Authority, in each case as in effect from time to time;

- 1.4. **"Appointed Date"** for the purpose of this Scheme and for the IT Act, means the opening of business hours on 1st April 2022;
- 1.5. **"Board of Directors"** or **"Board"** means the board of directors of the Transferor Companies or the Transferee Company, as the case may be, and shall include a duly constituted committee thereof or any person authorised by the Board or such committee;
- 1.6. **"BSE"** means BSE Limited;
- 1.7. **"Effective Date"** means the last of the dates on which the certified or authenticated copies of the orders of the Hon'ble National Company Law Tribunal sanctioning the Scheme are filed with the respective Registrar of Companies by the Transferor Companies and by the Transferee Company.
- Any references in this Scheme to the date of **"coming into effect of this Scheme"** or **"effectiveness of this Scheme"** or **"Scheme taking effect"** shall mean the Effective Date;
- 1.8. **"Eligible Employees"** means the employees who are eligible for the Stock Option Scheme of the Transferor Companies;
- 1.9. **"ESOP"** means the Employees Stock Option Scheme of the Transferor Companies pursuant to which eligible employees of the Transferor Companies are entitled to be issued shares in the Transferor Companies upon exercise of a stock option;
- 1.10. **"Governmental Authority"** means any applicable central, state or local government, legislative body, regulatory or administrative authority, agency or commission or any court, tribunal, board, bureau or instrumentality thereof or arbitration or arbitral body having jurisdiction over the territory of India including but not limited to Securities and Exchange Board of India, Stock Exchange, Registrar of Companies, Regional Director, Official Liquidator, NCLT;
- 1.11. **"Holding Company"** in relation to one or more other companies, means a company of which such companies are subsidiary companies;
- 1.12. **"ISO"** means International Organisation for Standardisation;
- 1.13. **"IT Act"** means the Income Tax Act, 1961 of India, including any statutory modifications, re-enactments or amendments thereof for the time being in force;
- 1.14. **"MAT Credit"** means Minimum Alternate Tax credit;
- 1.15. **"MEIS"** means Merchandise Exports from India Scheme;
- 1.16. **"NCLT"** means the National Company Law Tribunal, Bench at Mumbai, having jurisdiction in relation to the Transferee Company and the Transferor Companies;
- 1.17. **"NSE"** means National Stock Exchange India Limited;
- 1.18. **"Registrar of Companies"** means the Registrar of Companies, Maharashtra at Mumbai;
- 1.19. **"Regional Director"** means Regional Director, Western Region, Mumbai having jurisdiction in relation to the transferor companies and transferee company and/or the regional director ("RD") as constituted and authorized as per the provisions of the Companies act, 2013 for approving any scheme of arrangement, compromise or reconstruction of companies under section 230-232 of the Companies Act, 2013 and shall

include, if applicable, such other forum or authority as may be vested with the powers of a tribunal for the purpose of Sections 230-232 of the Companies Act, 2013 as may be applicable;

- 1.20. **"Record Date"** means the date to be fixed by the Board of Directors of the Transferee Company in consultation with the Board of Directors of the Transferor Companies which shall either be the Effective Date or a date after the Effective Date for the issue, allotment or cancellation of fully paid up equity shares of the Transferee Company to the shareholders or of the Transferor Companies pursuant to the Scheme upon amalgamation of the Transferor Companies into the Transferee Company;
- 1.21. **"Scheme"** means this Scheme of Amalgamation between the Transferor Companies and the Transferee Company and their respective shareholders pursuant to Sections 230 to 232 and other applicable provisions, if any, of the Companies Act, 2013 in its present form, and/or as submitted to the NCLT together with any modification(s) approved as directed by the NCLT;
- 1.22. **"SEBI"** means Securities and Exchange Board of India established through the SEBI Act, 1992;
- 1.23. **"SGST, CGST and IGST"** means the State Goods and Services Tax, the Central Goods and Services Tax and Integrated Goods and Services Tax;
- 1.24. **"Stock Exchange"** means BSE Limited and National Stock Exchange India Limited where the shares of the Transferee Company are listed;
- 1.25. **"Subsidiary Company or Subsidiary"** in relation to any other company (that is to say the holding company), means a company in which the holding company
- a. Controls the composition of the Board of Directors; or
 - b. Exercises or controls more than one-half of the [total voting power] either at its own or together with one or more of its subsidiary companies:
- Explanation for the purposes of this clause,
- a. A company shall be deemed to be a subsidiary company of the holding company even if the control referred to in sub-clause (a) or sub-clause (b) is of another subsidiary company of the holding company;
 - b. The composition of a company's Board of Directors shall be deemed to be controlled by another company if that other company by exercise of some power exercisable by it at its discretion can appoint or remove all or a majority of the Directors;
 - c. The expression "company" includes any body corporate;
- 1.26. **"Transferor Company No.1"** means **Ramdev Chemical Private Limited** (CIN:U24200MH1999PTC120863), a company incorporated under the Companies Act, 1956 having its registered office at Plot No.142-AB, Kandivli Industrial Estate, Kandivli (West), Mumbai City MH 400067 IN;

- 1.27. **"Transferor Company No.2"** means **Tonira Exports Limited**(CIN:U51909MH1995PLC248308), a company incorporated under the Companies Act, 1956 having its registered office at 142AB, Kandivli Industrial Estate, Kandivli (West), Mumbai City MH 400067 IN;
- 1.28. **"Transferor ESOP Scheme"** means the Employees Stock Option Scheme of the Transferor Companies pursuant to which eligible employees of the Transferor Companies are entitled to be issued shares in the Transferor Companies upon exercise of a stock option;
- 1.29. **"Transferor Option"** means a stock option granted under an ESOP Scheme of the Transferor Companies;
- 1.30. **"Tax(s)"** means the advance tax, the tax deducted at source, deferred tax payment, the income tax under IT Act and any such direct or indirect taxes, including GST as may be applicable to the Transferor and Transferee Companies;
- 1.31. **"Transferee Company"** means **Ipca Laboratories Limited** (CIN: L24239MH1949PLC007837) a company incorporated under the Companies Act, 1913 having its registered office at 48, Kandivli Industrial Estate. Kandivli (W), Mumbai MH 400067 IN;
- 1.32. **"Undertaking"** means the whole of the undertaking and entire business of the Transferor Companies as a going concern, including (without limitation):
- I. All the assets and properties (whether movable or immovable, tangible or intangible, real or personal, corporeal or incorporeal, present, future or contingent) of the Transferor Companies, including but not limited to land (freehold/leasehold), plant and machinery, equipment, buildings and structures, offices, residential and other premises, furniture, fixtures, office equipment, appliances, accessories, depots, deposits, all stocks, assets, investments of all kinds (including shares, scrips, stocks, bonds, debenture stocks, units), and interests, cash balances or deposits with banks, loans, advances, disbursements, contingent rights or benefits, book debts, receivables, actionable claims, insurance claims, insurance policies, earnest moneys, advances or deposits paid by the Transferor Companies, financial assets, leases (including lease rights), hire purchase contracts and assets, lending contracts, rights and benefits under any agreement, benefit of any security arrangements or under any guarantees, reversions, powers, municipal permissions, tenancies in relation to the office and/or residential properties for the employees or other persons, guest houses, godowns, warehouses, licenses, fixed and other assets, trade and service names and marks, patents, copyrights, and other intellectual property rights of any nature whatsoever, know how, goodwill, rights to use and avail of telephones, telexes, facsimile, email, internet, leased line connections and installations, utilities, electricity and other services, reserves, provisions, funds, benefits of assets or properties or other interest held in trust, subsidiaries, joint ventures, associates, registrations, contracts, engagements, arrangements of all kind, privileges and all

other rights including, title, interests, other benefits (including tax benefits), easements, privileges, liberties, mortgages, hypothecations, pledges or other security interest so created in favour of the Transferor Companies and advantages of whatsoever nature and wheresoever situated in India or abroad, belonging to or in the ownership, power or possession and in the control of or vested in or granted in favour of or enjoyed by the Transferor Companies or in connection with or relating to the Transferor Companies and all other interests of whatsoever nature belonging to or in the ownership, power, possession or the control of or vested in or granted in favour of or held for the benefit of or enjoyed by the Transferor Companies, whether in India or abroad;

- II. All liabilities including, without being limited to, secured and unsecured debts (whether in Indian rupees or foreign currency), sundry creditors, liabilities (including contingent liabilities), duties and obligations of the Transferor Companies, of every kind, nature and description whatsoever and howsoever arising, raised or incurred or utilised;
- III. All agreements, rights, contracts, entitlements, permits, licenses, approvals, authorizations, concessions, consents, quota rights, engagements, arrangements, authorities, allotments, security arrangements (to the extent provided herein), benefits of any guarantees, reversions, powers and all other approvals of every kind, nature and description whatsoever relating to the Transferor Companies;
- IV. All records, files, papers, computer programs, manuals, data, catalogues, sales material, lists of customers and suppliers, other customer information and all other records and documents relating to the business activities and operations of the Transferor Companies;
- V. All permanent employees engaged by the Transferor Companies as on the Effective Date.
- VI. All quotas, rights, entitlements, export/import incentives and benefits including advance licenses, MEIS, all kinds of duty drawbacks, bids, tenders (at any stage as it may be), letters of intent, expressions of interest, development rights (whatever vested or potential and whether under agreements or otherwise), subsidies, tenancies in relation to office, benefit of any deposits / privileges, all other rights, receivables, powers and facilities of every kind, nature and description whatsoever, rights to use and avail of telephones, telexes, facsimile connections and installations, utilities, electricity and other services, provisions and benefits of all agreements, contracts and arrangements, including technological licensing agreements, and benefits including but not limiting to all other interests in connection with or relating thereto;

VII. All brand names, trademarks, trade names, patents and domain names, the intellectual property in relation to ANDAs(Abbreviated New Drug Application), Certificate of Pharmaceutical Products (CoPPs), Certificate of Suitability (CoS) registrations; applications and authorizations of pharmaceutical products with governmental authorities in any jurisdiction (in so far as such pharmaceutical products pertain to the Undertaking), filings, dossiers, copyrights, industrial designs, trade secrets, know-how; ongoing research projects, data, formulations, technology, methodology, manufacturing procedures and techniques, test procedures, product registrations, applications and authorizations, Star Export House recognition and other intellectual property (in India or outside India) and all other interests exclusively relating to the goods or services being dealt with by the Transferor Companies;

VIII. All intellectual property rights created, developed or invented by employees concentrated on the research, development or marketing of products (including process development or enhancement) in connection with the Transferor Companies;

IX. All benefits and privileges under letters of permission and letters of approvals in respect of Special Economic Zones and Export Oriented Units and the benefits related thereto, all tax credits, including SGST, CGST and IGST credits, refunds, reimbursements, claims, exemptions, benefits under service tax laws, value added tax, purchase tax, sales tax, MEIS, Entry tax or any other duty or tax or cess or imposts under central or state law including sales tax deferrals, advance taxes, tax deducted at source, right to carry forward and set-off unabsorbed losses, if any and depreciation, MAT Credit, deductions and benefits under the IT Act, as well as any recognition of the In-house Research and Development unit with the Department of Scientific & Industrial Research or any Government Authority;

1.33. **“US FDA”** means United States Food and Drugs Administration;

1.2. All capitalized terms not defined but used in this Scheme shall, unless repugnant or contrary to the context or meaning thereof, have the same meaning as described to them under the Act, the Securities Contracts (Regulation) Act, 1956, the Depositories Act, 1996 and other applicable laws, rules, regulations and byelaws, as the case may be, or any statutory amendment(s) or re-enactment thereof, for the time being in force.

2. SHARE CAPITAL

2.1. Transferor Company No.1 :

The Authorised, Issued, Subscribed and Paid-up share capital of the Transferor Company no. 1 as on March 31, 2022 was as under:

Particulars	Amount (INR)
Authorised Share Capital	
5,00,000 Equity Shares of INR 10/- each	50,00,000
Total	50,00,000
Issued, Subscribed and Paid Up Share Capital	
5,00,000 Equity Shares of INR 10/- each	50,00,000
Total	50,00,000

Subsequent to March 31, 2022 there is no change in the capital structure of the Transferor Company. Transferor Company is wholly owned subsidiary of the Transferee Company as 100% issued, subscribed and paid up share capital of the Transferor Company is held by the Transferee Company as on the date.

2.2. Transferor Company No.2:

The Authorised, Issued, Subscribed and Paid-up share capital of the Transferor Company No. 2 as on March 31, 2022 was as under:

Particulars	Amount (INR)
Authorised Share Capital	
1,00,000 Equity Shares of INR 10/- each	10,00,000
Total	10,00,000
Issued, Subscribed and Paid Up Share Capital	
1,00,000 Equity Shares of INR 10/- each	10,00,000
Total	10,00,000

Subsequent to March 31, 2022 there is no change in the capital structure of the Transferor Company. Transferor Company is wholly owned subsidiary of the Transferee Company as 100% issued, subscribed and paid up share capital of the Transferor Company is held by the Transferee Company as on the date.

2.3. Transferee Company:

The Authorised, Issued, Subscribed and Paid-up share capital of the Transferee Company as on March 31, 2022 was as under:

Particulars	Amount (INR)
Authorised Share Capital	
57,00,00,000 Equity Shares of INR. 1/- each	57,00,00,000
Total	57,00,00,000
Issued and Subscribed Share Capital	
25,62,66,408 Equity Shares of INR. 1/- each	25,62,66,408
Total	25,62,66,408
Paid Up Share Capital	
25,37,04,218 Equity Shares of INR. 1/- each	25,37,04,218
Total Paid Up Share Capital	25,37,04,218

Subsequent to March 31, 2022 there is no change in the capital structure of the Transferee Company.

The equity shares of Transferee Company are, at present, listed on the BSE Limited and National Stock Exchange India Limited.

3. DATE OF TAKING EFFECT AND OPERATIVE DATE

The Scheme set out herein in its present form or with any modifications approved or imposed or directed by NCLT shall be effective from the Appointed Date but shall be operative from the Effective Date.

PART II

TRANSFER AND VESTING OF UNDERTAKING

4. TRANSFER OF UNDERTAKING

- 4.1. Upon the coming into effect of this Scheme and with effect from the Appointed Date, the Undertaking, pursuant to the sanction of this Scheme by NCLT under and in accordance with the provisions of Sections 230 to 232 and other applicable provisions, if any, of the Act, shall stand transferred to and be vested in or be deemed to have been transferred to and vested in the Transferee Company, as a going concern without any further act, instrument, deed, matter or thing to be made, done or executed so as to become, as and from the Appointed Date, the Undertaking of the Transferee Company by virtue of and in the manner provided in this Scheme.
- 4.2. Subject to the provisions of this Scheme as specified hereinafter and with effect from the Appointed Date, the entire Undertaking(s) of the Transferor Companies, including all the debts, liabilities, losses, duties and obligations, including those arising on account of taxation laws and other allied laws of the Transferor Companies of every description and

also including, without limitation, all the movable and immovable properties and assets, Tangible or Intangible assets (whether or not recorded in the books of account of the Transferor Companies) of the Transferor Companies comprising, amongst others, all freehold land including a freehold land, all leasehold land including leasehold land, buildings, plants and machineries, motor vehicles, manufacturing facilities, laboratories, furniture and fixtures, computers, computer software and its licenses, office equipments, electrical installations, generators, containers, telephones, telex, facsimile and other communication facilities, receivables, actionable claims, insurance claims, business licenses, licenses under Factories Act, manufacturing licenses, permits, deposits, authorisations, approvals (including under MEIS), recognitions including Star Export House, Certificate of Suitability for products, WHO-GMP (World Health Organisation – Goods Manufacturing Practices) certifications, ISO 9001:2008, ISO 14001:2004, FAMI-QS (Feed Additive and Premixture Quality System), BS OHSAS 18001:2007 (Occupational Health and Safety Assessment Series), HACCP(Hazard Analysis and Critical Control Points), Halal, Kosher, Vegetarian Society Certificate, United Kingdom, American Vegetarian Association Certificate, US FDA EIR (Establishment Inspection Report)and any other certificates relating to the product, factory facilities and registrations granted by the Department of Scientific & Industrial Research to the in-house research and development units established, insurance cover of every description, lease, tenancy rights, permissions, incentives, if any, and all other rights, patents, know-how, trademark, service mark, trade secret, brands, registrations, licenses including Export Oriented Unit licences/advance licences, Special Economic Zones registrations, marketing authorisations and other intellectual property rights, proprietary rights, title, interest, contracts, no objection certificates, deeds, bonds, consents, approvals and rights and powers of every kind, nature and description whatsoever, privileges, liberties, easements, advantages and benefits, approvals, filings, dossiers, copyrights, industrial designs, trade secrets, know-how, ongoing research projects, data, formulations, technology, methodology, manufacturing procedures and techniques, test procedures, brand names, trade names and domain names, and all other interests in connection with or relating to and product registrations, applications and authorisations for product registrations and all other interests exclusively relating to the SGST, CGST and IGST, Good Manufacturing Practice Certificates, Abbreviated New Drug Applications approved by the U.S. Food and Drug Administration and others including Certificate of Suitability (COS), WHO-GMP US FDA EIR, Certificate of Suitability (CEP) shall, under the provisions of Sections 230 to 232 of the Act, and pursuant to the order of the NCLT, sanctioning this Scheme and without further act, instrument or deed, but subject to the charges affecting the same as on the Effective Date, be transferred and/or deemed to be transferred to and vested in the Transferee Company, so as to become the properties, assets, rights, business, certificates and Undertaking of the Transferee Company.

4.3. Transfer of Assets:

4.3.1. Without prejudice to the generality of Clause 4.1 and 4.2 above, upon the coming into effect of this Scheme and with effect from the Appointed Date:

4.3.1.1. All the assets and properties comprised in the Undertaking(s) of whatsoever nature and wheresoever situated, shall, under the provisions of Sections 230 to 232 and all other applicable provisions, if any of the Act, without any further act or deed, be and stand transferred to and vested in the Transferee Company or be deemed to be transferred to and vested in the Transferee Company as a going concern so as to become the assets and properties of the Transferee Company. The assets of Transferor Companies, including immovable properties, shall transfer to Transferee Company without any further act or deed.

4.3.1.2. Without prejudice to the provisions of Clause 4.3.1.1. above, in respect of such of the assets and properties of the Undertakings as are movable in nature or incorporeal property or are otherwise capable of transfer by manual delivery or by endorsement and/or delivery, the same shall be so transferred by the Transferor Companies and shall, upon such transfer, become the assets and properties of the Transferee Company as an integral part of the Undertakings, without requiring any separate deed or instrument or conveyance for the same.

4.3.1.3. In respect of movables other than those dealt with in Clause 4.3.1.2 above including sundry debts, receivables, insurance claims, bills, credits, loans and advances of the Undertaking, if any, whether recoverable in cash or in kind or for value to be received, bank balances, investments, earnest money and deposits with any Governmental Authority or with any company or other person, the same shall on and from the Appointed Date stand transferred to and vested in the Transferee Company.

4.3.1.4. All interests of the Transferor Companies in their respective subsidiaries as on the Appointed Date will become the interests and subsidiaries of the Transferee Company.

4.3.1.5. All the licenses, permits, quotas, approvals, permissions, registrations, incentives, tax deferrals and benefits, subsidies, concessions, grants, rights, claims, leases, tenancy rights, liberties, special status and other benefits or privileges enjoyed or conferred upon or held or availed of by the Transferor Companies and all rights and benefits that have accrued or which may accrue to the Transferor Companies, whether before or after the Appointed Date, shall, under the provisions of Sections 230 to 232 and all other applicable

provisions, if any, of the Act, without any further act, instrument or deed, cost or charge be and stand transferred to and vest in or be deemed to be transferred to and vested in and be available to the Transferee Company so as to become as and from the Appointed Date licenses, permits, quotas, approvals, permissions, registrations, incentives, tax deferrals and benefits, subsidies, concessions, grants, rights, claims, leases, tenancy rights, liberties, special status and other benefits or privileges of the Transferee Company and shall remain valid, effective and enforceable on the same terms and conditions.

4.3.2. The Transferor Companies shall, if so required, also give notice in such form as it may deem fit and proper to the debtors/vendors, that pursuant to the sanction of this Scheme by NCLT, under and in accordance with Sections 230 and 232 and all other applicable provisions, if any, of the Act, the said debtors/vendors should pay to the Transferee Company the debt, loan or advance or make the same on account of the Transferor Companies and the right of the Transferor Companies to recover or realize the same stands extinguished.

4.3.3. All assets and properties of the Transferor Companies as on the Appointed Date, whether or not included in the books of the Transferor Companies, and all assets and properties which are acquired by the Transferor Companies on or after the Appointed Date but prior to the Effective Date, shall be deemed to be and shall become the assets and properties of the Transferee Company, and shall under the provisions of Sections 230 to 232 and all other applicable provisions, if any, of the Act, without any further act, instrument or deed, be and stand transferred to and vested in and be deemed to have been transferred to and vested in the Transferee Company upon the coming into effect of this Scheme. Provided however that no onerous assets shall have been acquired by the Transferor Companies after the Appointed Date without the consent of the Transferee Company as provided for in this Scheme.

4.4. Transfer of Liabilities:

4.4.1. Upon the coming into effect of this Scheme and with effect from the Appointed Date, all liabilities relating to and comprised in the Undertakings including all secured and unsecured debts (whether in Indian rupees or foreign currency), sundry creditors, liabilities (including contingent liabilities), duties and obligations and undertakings of the Transferor Companies of every kind, nature and description whatsoever and howsoever arising, raised or incurred or utilised for its business activities and operations (herein referred to as the "**Liabilities**"), shall, pursuant to the sanction of this Scheme by the NCLT under and in accordance with the provisions of Sections 230 to 232 and other applicable provisions, if any, of the Act, without any further act, instrument, deed, matter or thing, be transferred to and

vested in or be deemed to have been transferred to and vested in the Transferee Company, along with any charge, encumbrance, lien or security thereon, and the same shall be assumed by the Transferee Company to the extent they are outstanding as on the Effective Date so as to become as and from the Appointed Date the liabilities of the Transferee Company on the same terms and conditions as were applicable to the Transferor Companies, and the Transferee Company shall meet, discharge and satisfy the same and, further, it shall not be necessary to obtain the consent of any third party or other person who is a party to any contract or arrangement by virtue of which such Liabilities have arisen in order to give effect to the provisions of this Clause.

4.4.2. All debts, liabilities, duties and obligations of the Undertakings as on the Appointed Date, whether or not provided in the books of the Transferor Companies, and all debts and loans raised, and duties, liabilities and obligations incurred or which arise or accrue to the Undertakings on or after the Appointed Date till the Effective Date, shall be deemed to be and shall become the debts, loans raised, duties, liabilities and obligations incurred by the Transferee Company by virtue of this Scheme.

4.4.3. Where any such debts, loans raised, liabilities, duties and obligations of the Undertakings as on the Appointed Date have been discharged or satisfied by the Transferor Companies after the Appointed Date and prior to the Effective Date, such discharge or satisfaction shall be deemed to be for and on account of the Transferee Company.

4.4.4. Loans, advances and other obligations (including any guarantees, letters of credit, letters of comfort or any other instrument or arrangement which may give rise to a contingent liability in whatever form), if any, due or which may at any time in future become due between the Undertaking and the Transferee Company shall, *ipso facto*, stand discharged and come to an end and there shall be no liability in that behalf on any party and appropriate effect shall be given in the books of accounts and records of the Transferee Company.

4.5. Encumbrances

4.5.1. The transfer and vesting of the assets comprised in the Undertaking to and in the Transferee Company under Clauses 4.1, 4.2 and 4.3 of this Scheme shall be subject to the mortgages and charges, if any, affecting the same, as and to the extent hereinafter provided.

4.5.2. All the existing securities, mortgages, charges, encumbrances or liens (the "Encumbrances"), if any, as on the Appointed Date and created by the Transferor Companies after the Appointed Date, over the assets comprised in the Undertakings or any part thereof transferred to the Transferee Company by virtue of this Scheme

and in so far as such Encumbrances secure or relate to liabilities of the Transferor Companies, the same shall, after the Effective Date, continue to relate and attach to such assets or any part thereof to which they are related or attached prior to the Effective Date and as are transferred to the Transferee Company, and such Encumbrances shall not relate or attach to any of the other assets of the Transferee Company, provided however that no Encumbrances shall have been created by the Transferor Companies over its assets after the Appointed Date without the consent of the Transferee Company as provided for in this Scheme.

4.5.3. The existing Encumbrances over the assets and properties of the Transferee Company or any part thereof which relate to the liabilities and obligations of the Transferee Company prior to the Effective Date shall continue to relate only to such assets and properties and shall not extend or attach to any of the assets and properties of the Undertaking transferred to and vested in the Transferee Company by virtue of this Scheme.

4.5.4. Any reference in any security documents or arrangements (to which the Transferor Companies are a party) to the Transferor Companies and its assets and properties, shall be construed as a reference to the Transferee Company and the assets and properties of the Transferor Companies transferred to the Transferee Company by virtue of this Scheme. Without prejudice to the foregoing provisions, the Transferor Companies and the Transferee Company may execute any instruments or documents or do all the acts and deeds as may be considered appropriate, including the filing of necessary particulars and/or modification(s) of charge(s), with the Registrar of Companies to give formal effect to the above provisions, if required.

4.5.5. Upon the coming into effect of this Scheme, the Transferee Company alone shall be liable to perform all obligations in respect of the Liabilities of Transferor Companies, which have been transferred to it in terms of the Scheme.

4.5.6. It is expressly provided that, no other term or condition of the Liabilities transferred to the Transferee Company is modified by virtue of this Scheme except to the extent that such amendment is required statutorily or by necessary implication.

4.5.7. The provisions of this Clause 4.5 shall operate in accordance with the terms of the Scheme, notwithstanding anything to the contrary contained in any instrument, deed or writing or the terms of sanction or issue or any security document; all of which instruments, deeds or writings shall be deemed to stand modified and/or superseded by the foregoing provisions.

4.6. **Inter - se Transactions:**

Without prejudice to the provisions of Clauses 4.1 to 4.5, with effect from the Appointed Date, all inter-se transactions between the Transferor Companies and the Transferee Company shall be considered as intra-se transactions for all purposes. Further, it is clarified that any taxes in the form of income-tax, goods and service tax, service tax, works contract tax, value added tax etc paid on account of such transactions, shall be deemed to

have been paid by or on behalf of the Transferee Company and on its own account and therefore, the Transferee Company will be eligible to claim the credit / refund of the same and is also entitled to revise its return to give effect to the same.

5. CONTRACTS, DEEDS, ETC.

- 5.1. Upon the coming into effect of this Scheme and subject to the provisions of this Scheme, all contracts, deeds, bonds, agreements, schemes, arrangements, assurances and other instruments of whatsoever nature to which the Transferor Companies is a party or to the benefit of which the Transferor Companies may be eligible, and which are subsisting or have effect immediately before the Effective Date, shall continue in full force and effect by, for or against or in favour of, as the case may be, the Transferee Company and may be enforced as fully and effectually as if, instead of the Transferor Companies, the Transferee Company had been a party or beneficiary or obligee or obligor thereto or thereunder.
- 5.2. Without prejudice to the other provisions of this Scheme and notwithstanding the fact that vesting of the Undertaking occurs by virtue of this Scheme itself, the Transferee Company may, at any time after the coming into effect of this Scheme in accordance with the provisions hereof, if so required under any law or otherwise, take such actions and execute such deeds (including deeds of adherence), confirmations or other writings or arrangements with any party to any contract or arrangement to which the Transferor Companies is a party or any writings as may be necessary in order to give formal effect to the provisions of this Scheme. The Transferee Company shall, under the provisions of this Scheme, be deemed to be authorised to execute any such writings on behalf of the Transferor Company and to carry out or perform all such formalities or compliances referred to above on the part of the Transferor Companies from the Appointed Date and upto the Effective Date and, thereafter, for such period as may be decided by the Board of the Transferee Company to give effect to the Scheme.
- 5.3. For the avoidance of doubt and without prejudice to the generality of the foregoing, it is clarified that upon the coming into effect of this Scheme, all consents, permissions, licenses, certificates, clearances, authorities, powers of attorney given by, issued to or executed in favour of the Transferor Companies shall without any further act or deed, stand transferred to the Transferee Company, as if the same were originally given by, issued to or executed in favour of the Transferee Company, and the Transferee Company shall be bound by the terms thereof, the obligations and duties there under, and the rights and benefits under the same shall be available to the Transferee Company. The Transferee Company shall receive relevant approvals from the concerned Governmental Authorities as may be necessary in this behalf.

6. LEGAL PROCEEDINGS

On and from the Appointed Date, all suits, actions, claims and legal proceedings by or against the Transferor Companies pending and/or arising on or before the Effective Date

shall be continued and / or enforced as desired by the Transferee Company and on and from the Effective Date, shall be continued and/or enforced by or against the Transferee Company as effectually and in the same manner and to the same extent as if the same had been originally instituted and/or pending and/or arising by or against the Transferee Company. On and from the Effective Date, the Transferee Company shall have the right to initiate, defend, compromise or otherwise deal with any legal proceedings relating to the Undertaking, in the same manner and to the same extent as would or might have been initiated by the Transferor Companies as the case may be, had the Scheme not been made. If any suit, appeal or other proceedings relating to the Undertakings, of whatever nature by or against the Transferor Companies be pending, the same shall not abate or be discontinued or in any way be prejudicially affected by reason of the amalgamation of the Undertaking or by anything contained in this Scheme but the proceedings may be continued, prosecuted and enforced by or against the Transferee Company in the same manner and to the same extent as it would or might have been continued, prosecuted and enforced by or against the Transferor Companies as if this Scheme had not been made.

7. CONDUCT OF BUSINESS

7.1. With effect from the Appointed Date and up to and including the Effective Date:

7.1.1. The Transferor Companies shall carry on and shall be deemed to have carried on all its business and activities as hitherto and shall hold and stand possessed of and shall be deemed to have held and stood possessed of the Undertaking on account of, and for the benefit of and in trust for, the Transferee Company.

7.1.2. All the profits or income accruing or arising to the Transferor Companies, and all expenditure or losses arising or incurred (including all taxes, if any, paid or accruing in respect of any profits and income) by the Transferor Companies shall, for all purposes, be treated and be deemed to be and accrue as the profits or income or as the case may be, expenditure or losses (including taxes) of the Transferee Company.

7.1.3. Any of the rights, powers, authorities and privileges attached or related or pertaining to and exercised by or available to the Transferor Companies shall be deemed to have been exercised by the Transferor Companies for and on behalf of and as agent for the Transferee Company. Similarly, any of the obligations, duties and commitments attached, related or pertaining to the Undertaking that have been undertaken or discharged by the Transferor Companies shall be deemed to have been undertaken or discharged for and on behalf of and as agent for the Transferee Company.

7.2. With effect from the date of approval of this Scheme by the Board of the respective companies and up to and including the Effective Date:

7.2.1. The Transferor Companies shall preserve and carry on their business and activities with reasonable diligence and business prudence and shall not undertake any

additional financial commitments of any nature whatsoever, borrow any amounts nor incur any other liabilities or expenditure, issue any additional guarantees, indemnities, letters of comfort or commitments either for itself or on behalf of its group Company or any third party or sell, transfer, alienate, charge, mortgage or encumber or deal with the Undertakings or any part thereof save and except in each case in the following circumstances:

- 7.2.1.1. if the same is in its ordinary course of business as carried on by it as on the date of filing this Scheme with NCLT; or
- 7.2.1.2. if the same is permitted by this Scheme; or
- 7.2.1.3. if consent of the Board of Directors of the Transferee Company has been obtained.

7.2.2. The Transferor Companies shall not take, enter into, perform or undertake, as applicable (i) any material decision in relation to its business and operations other than decisions already taken prior to approval of the Scheme by the Board of Directors of the Transferor Companies (ii) any agreement or transaction; and (iii) any new business, or discontinue any existing business or change the capacity of facilities; (iv) such other matters as the Transferee Company may notify from time to time save and except in each case in the following circumstances:

- 7.2.2.1. if the same is in its ordinary course of business as carried on by it as on the date of filing this Scheme with NCLT; or
- 7.2.2.2. if the same is permitted by this Scheme; or
- 7.2.2.3. if consent of the Board of Directors of the Transferee Company has been obtained.

8. STAFF WORKMEN AND EMPLOYEES

Upon the coming into effect of this Scheme:

- 8.1. All the permanent employees of the Transferor Companies who are in its employment as on the Effective Date shall become the permanent employees of the Transferee Company with effect from the Effective Date without any break or interruption in service and on terms and conditions as to employment and remuneration not less favourable than those on which they are engaged or employed by the Transferor Companies. It is clarified that the employees of the Transferor Companies who become employees of the Transferee Company by virtue of this Scheme, shall not be entitled to the employment policies and shall not be entitled to avail of any schemes and benefits that may be applicable and available to any of the employees of the Transferee Company (including the benefits of or under any employee stock option schemes applicable to or covering all or any of the employees of the Transferee Company), unless otherwise determined by the Board of Directors of the Transferee Company. The Transferee Company undertakes to continue to abide by any agreement/ settlement, if any, validly entered into by the Transferor

Companies with any union/employee of the Transferor Companies (as may be recognized by the Transferor Companies).

- 8.2. The existing provident fund, gratuity fund and pension and/or superannuation fund or trusts or retirement funds or benefits created by the Transferor Companies or any other special funds created or existing for the benefit of the concerned permanent employees of the Transferor Companies (collectively referred to as the "Funds") and the investments made out of such Funds shall, at an appropriate stage, be transferred to the Transferee Company to be held for the benefit of the concerned employees. The Funds shall, subject to the necessary approvals and permission and at the discretion of the Transferee Company, either be continued as separate funds of the Transferee Company for the benefit of the employees of the Transferor Companies or be transferred to and merged with other similar funds of the Transferee Company. In the event that the Transferee Company does not have its own fund with respect to any such Funds, the Transferee Company may, subject to necessary approvals and permissions, continue to maintain the existing Funds separately and contribute thereto, until such time as the Transferee Company creates its own funds at which time the Funds and the investments and contributions pertaining to the employees of the Transferor Companies shall be transferred to such funds of the Transferee Company.
-

PART III

9. INCREASE IN AUTHORIZED SHARE CAPITAL OF TRANSFeree COMPANY

- 9.1. Upon the Scheme coming into effect, the authorised share capital of the Transferor Companies (i.e. INR 60,00,000/- (Rupees Sixty Lacs) shall be added to that of the Transferee Company and in the Memorandum of Association and Articles of Association Transferee Company, it shall be automatically stand enhanced without any further act, instrument or deed on the part of the Transferee Company, including payment of stamp duty and fees payable to Registrar of Companies and the Memorandum of Association and Articles of Association of the Transferee Company (relating to the authorized share capital) shall, without any further act, instrument or deed, be and stand altered, modified and amended, and the consent of the shareholders to the Scheme shall be deemed to be sufficient for the purposes of effecting this amendment and no further resolution(s) under sections 13, 14, 61 and 64 of the Companies Act, 2013 or any other applicable provisions of the Companies Act 2013, would be required to be separately passed. For this purpose, the filing fees and stamp duty already paid by the Transferor Companies on the authorised share capital shall be utilized and applied to the increased share capital of the Transferee Company and shall be deemed to have been so paid by the Transferee Company on such combined authorised share capital and accordingly, the Transferee Company shall not be required to pay any fees / stamp duty on the authorised share capital so increased.

- 9.2. The capital clause being Clause V of the Memorandum of Association of the Transferee Company shall on the Effective Date stand substituted to read as follows:

“The Authorised Share Capital of the Company is Rs. 57,60,00,000/- (Rupees Fifty Seven Crores Sixty Lacs Only) divided into 57,60,00,000 (Fifty Seven Crores Sixty Lacs) Equity Shares of Re. 1/- (Rupee One) each with power to increase or decrease the capital and divide the shares in capital for the time being into several classes and to attach thereto respectively such ordinary, preferential shares, qualified or special rights or privileges and conditions in such manner as may for the time being, provided by the regulations of the Company and as permissible under the statutory provisions in force.”

10. CANCELLATION OF SHARES OF THE TRANSFEROR COMPANY(IES)

- 10.1. In light of the fact that upon the amalgamation of Transferor Companies into Transferee Company, since each of Transferor Companies would qualify as a wholly owned subsidiary of Transferee Company, there will be no consideration whether in the form of issues of shares or otherwise that would be applicable or be paid as a result of the amalgamation of Transferor Companies with Transferee Company.
- 10.2. Upon the Scheme becoming finally effective, in consideration of the transfer and vesting of the Transferor companies in the Transferee Company in terms of the Scheme, the Transferor Companies and the Transferee Company shall subject to the provisions of the Scheme and without any further application, act or deed, cancel the issued and paid up capital of the Transferor Companies held by the Transferee Company.
- 10.3. Upon this Scheme becoming effective, the Shares held by the Transferor Companies and the Transferee Company, inter se, in each other and amongst Transferor Companies shall be cancelled and no shares will be issued against them. It shall be deemed that the provisions of Sections 66 of the Companies Act 2013 (Act) and/or any other applicable provisions of the Act, rules and regulations framed there under have been complied with.
- 10.4. The Share Certificates in relation to the shares held by the Equity Shareholders of the Transferor Companies whose names are recorded in the Register of Members of the Transferor Companies on the Record Date, fixed by the Board of Directors of the Transferee Company, shall be deemed to have been automatically cancelled and be of no effect on and from such Record Date, without any further act, instrument or deed.
- 10.5. As both the Transferor Companies are wholly owned subsidiary of the Transferee Company, no Shares of Transferee Company will be issued to any Shareholder, including Nominee Shareholder(s), of Transferor Companies.

PART IV
ACCOUNTING TREATMENT

11. ACCOUNTING TREATMENT IN THE BOOKS OF ACCOUNT OF TRANSFEREE COMPANY

The Transferee Company shall account for amalgamation in accordance with Indian Accounting Standard ("IND AS") 103 – "Business Combinations" prescribed under Section 133 of the Act and other generally accepted accounting principles in India.

The Transferee Company shall account for the transfer and vesting of the Assets and Liabilities of the Undertakings of Transferor Companies in its books of accounts as per the "Pooling of Interest" method prescribed under Appendix C to Indian Accounting Standard - 103 - "Business Combinations" prescribed under Section 133 of the Act read with the relevant rules issued there under and other generally accepted accounting principles in India as under:

- The Transferee Company shall, record all the assets and liabilities of the Undertakings vested in it pursuant to this Scheme at the respective carrying amounts. The financial information in the financial statements of the Transferee Company, to be prepared after the amalgamation, in respect of prior periods will be restated to include the financial information of the Transferor Companies as if the business combination had occurred from the beginning of the preceding period in the financial statements.
- The identity of the reserves standing in the books of account of the Transferor Companies shall be preserved and they shall appear in the financial statements of the Transferee Company in the same form, as they appeared in the financial statements of the Transferor Companies.
- The balance of the retained earnings in the books of account of the Transferor Companies shall be aggregated with the corresponding balance of retained earnings of the Transferee Company.

As stated in Clause 10 above, no new shares will be issued or allotted by the Transferee Company, pursuant to this scheme, to the extent of paid up equity share of the Transferor Companies held by the Transferee Company, and the investments in the shares of the Transferor Companies appearing, inter alia, in the books of account of the Transferee Company shall stand cancelled. The inter-company deposits, loans & advances and other balances if any, in the books of the account of the Transferee Company and the Transferor Companies shall stand discharged and come to an end and the same shall be eliminated by giving appropriate elimination effect in the books of account and records of the Transferee Company.

- In case there is any difference in the accounting policies adopted by the Transferor Companies and the Transferee Company, the accounting policies followed by the

Transferee Company will prevail and the difference will be quantified and adjusted in accordance with the Indian Accounting Standards.

- In addition, the Transferee Company shall pass such accounting entries, as may be necessary, in connection with this Scheme to comply with any of the applicable Indian Accounting Standards and other generally accepted accounting principles in India.

12. TAX BENEFITS AND OBLIGATIONS

- 12.1. The amalgamation of the Transferor Companies with the Transferee Company in terms of this Scheme shall take place with effect from the Appointed Date and shall be in accordance with the provisions of Sections 2(1B), 47, 72A and 79 and any other application provisions of the IT Act.
- 12.2. Upon the Scheme becoming effective, all Taxes payable by, or refundable to, the Transferor Companies, including any refunds, claims or credits (including credits for income Tax, withholding Tax, advance Tax, self-assessment Tax, minimum alternate Tax, CENVAT credit, goods and services Tax credits, other indirect Tax credits and other Tax receivables) shall be treated as the Tax liability, refunds, claims, or credits, as the case may be, of the Transferee Company, and any Tax incentives, benefits (including claims for unabsorbed Tax losses and unabsorbed Tax depreciation), advantages, privileges, exemptions, credits, Tax holidays, remissions or reductions, which would have been available to the Transferor Companies, shall be available to the Transferee Company, and following the Effective Date, the Transferee Company shall be entitled to initiate, raise, add or modify any claims in relation to such Taxes on behalf of the Transferor Companies.
- 12.3. The provisions of this Scheme as they relate to the amalgamation of the Transferor Companies into and with the Transferee Company have been drawn up to comply with the conditions relating to "amalgamation" as defined under Section 2(1B) of the IT Act. If any terms or provisions of the Scheme are found or interpreted to be inconsistent with the provisions of the said Section of the IT Act, at a later date including resulting from an amendment of law or for any other reason whatsoever, the provisions of the said Section of the IT Act, shall prevail and the provisions of this Scheme shall stand modified to the extent determined necessary to comply with Section 2(1B) of the IT Act. Such modification will, however, not affect the other parts of the Scheme.
- 12.4. Any tax liabilities under the IT Act, Wealth Tax Act, 1957, Customs Act, 1962, Goods and Services Tax Act, 2017, any other Tax laws, service tax, luxury tax, entry tax or other applicable laws/ regulations (hereinafter in this Clause referred to as "Tax Laws") dealing with taxes/ duties/ levies allocable or related to the business of the Transferor Companies to the extent not provided for or covered by tax provision in the accounts made as on the date immediately preceding the Appointed Date shall be transferred to Transferee Company.

- 12.5. All taxes (including income tax, wealth tax, sales tax, customs duty, SGST, CGST and IGST, entry tax, luxury tax etc.) paid or payable by the Transferor Companies in respect of the operations and/or the profits of the business on and from the Appointed Date, shall be on account of the Transferee Company and, insofar as it relates to the tax payment (including without limitation income tax, wealth tax, sales tax, customs duty, SGST, CGST and IGST, entry tax, luxury tax, etc.), whether by way of deduction at source, advance tax or otherwise howsoever, by the Transferor Companies in respect of the profits or activities or operation of the business on and from the Appointed Date, the same shall be deemed to be the corresponding item paid by the Transferee Company, and shall, in all proceedings, be dealt with accordingly.
- 12.6. Any refund under the Tax Laws due to the Transferor Companies consequent to the assessments made on Transferor Companies and for which no credit is taken in the accounts as on the date immediately preceding the Appointed Date shall also belong to and be received by the Transferee Company.
- 12.7. Without prejudice to the generality of the above, all benefits including under the income tax (including benefits available to SEZ units u/s 10AA of the IT Act, MAT credit and TDS credit), sales tax, excise duty, entry tax law, customs duty, service tax, luxury tax, VAT, SGST, CGST and IGST, etc., to which the Transferor Companies is entitled to in terms of the applicable Tax Laws of the Union and State Governments, shall be available to and vest in the Transferee Company.

13. DECLARATION OF DIVIDEND

- 13.1. During the period between the Appointed Date and up to and including the Effective Date, the Transferor Companies shall not declare any dividend without the prior written consent of the Board of Directors of the Transferee Company.
- 13.2. The Transferor Companies and Transferee Company shall be entitled to declare and pay dividends only out of distributable profits or any other manner as permitted under the Act, earned by respective companies during the relevant financial year and shall not transfer any amount from the reserves for the purposes of payment of dividend. The dividend shall be declared by the companies only by mutual agreement between the Board of Directors of the Companies.
- 13.3. The holders of shares of the Transferor Companies and the Transferee Company shall, save as expressly provided otherwise in this Scheme, continue to enjoy their existing rights under their respective article of association including the right to receive dividends from the respective companies, of which they are members till the date, this Scheme finally takes effect i.e. the Effective Date.
- 13.4. It is clarified, however that the aforesaid provisions in respect of declarations of dividend are enabling provisions only and shall not be deemed to confer any right on any member of the Transferor Companies or Transferee Company to demand or claim or be entitled to any dividend which subject to the provisions of the said Act, shall be entirely on the

discretion of the Board of Directors and the approval of the shareholders of the respective companies.

14. POWER TO GIVE EFFECT TO THIS PART

- 14.1. The Transferee Company shall enter into and/ or issue and/ or execute deeds, writings or confirmations or enter into any tripartite arrangements, confirmations or novations, to which the Transferor Companies will, if necessary, also be party in order to give formal effect to the provisions of this Scheme, if so required. Further, the Transferee Company shall be deemed to be authorised to execute any such deeds, writings or confirmations on behalf of the Transferor Companies and to implement or carry out all formalities required on the part of the Transferor Companies to give effect to the provisions of this Scheme.
- 14.2. Upon coming into effect of the Scheme, the Transferee Company and/or the Transferor Companies shall, with reasonable dispatch / time lines apply for transition of all licenses and statutory registrations of the Transferee Company including but not limited to product registrations (including applications and authorizations for product registrations), manufacturing licenses, insurance policies, product permissions, certificates, market authorizations, regulatory agencies approvals, filings, dossiers (including experience and prequalification submissions), industrial licences, municipal permissions, approvals, consent, permits, quotas, registration with Food and Drug Administrations of various states/countries, incentives, subsidies and recognitions. The period between the Effective Date and the last date on which the transfer of all such aforementioned licenses and statutory registrations have occurred is hereinafter referred to as "Transitory Period". During the Transition Period the Transferee Company, may procure or use or manufacture or sell, all materials and products under the respective country registrations including the packing material, art work, label, goods, cartons, stickers, wrappers, labels, containers, point of sale material, signboard, samples, closures, publicity materials in the name and form/format of the Transferor Companies under any license and/or statutory registration, if any, while conducting the business of the Undertakings, with a view to avoid any disruption of business, to ensure continuity of operations and uninterrupted supply of the registered products for domestic and export purposes.
- 14.3. Even after the Scheme becomes operative, the Transferee Company shall be entitled to operate all Bank Accounts and use all bank guarantees and letter of credit of the Transferor Companies, relating to the Undertakings and release all monies and complete and enforce all subsisting contracts and transactions in respect of the Transferor Companies in the name of Transferor Companies in so far as may be necessary, till the transfer of rights and obligations of the Transferor Companies to the Transferee Company until this Scheme is formally accepted by the all the parties concerned.
-

PART V
DISSOLUTION OF TRANSFEROR COMPANIES
AND
GENERAL TERMS AND CONDITIONS

15. DISSOLUTION OF TRANSFEROR COMPANIES

On the coming into effect of this Scheme, the Transferor Companies shall stand dissolved without winding-up, and the Board of Directors and any committees thereof of the Transferor Companies shall without any further act, instrument or deed be and stand dissolved.

16. VALIDITY OF EXISTING RESOLUTIONS, ETC.

Upon the coming into effect of this Scheme, the resolutions, if any, of the Transferor Companies, which are valid and subsisting on the Effective Date, shall continue to be valid and subsisting and be considered as resolutions of the Transferee Company and if any such resolutions have any monetary limits approved under the provisions of the Act, or any other applicable statutory provisions, then the said limits shall be added to the limits, if any, under like resolutions passed by the Transferee Company and shall constitute the aggregate of the said limits in the Transferee Company.

17. MODIFICATION OF SCHEME

- 17.1. Subject to approval of NCLT, the Transferor Companies and the Transferee Company by their respective Board of Directors or any director/executives or any committee authorised in that behalf (herein after referred to as the "**Delegate**") may assent to, or make, from time to time, any modification(s) or addition(s) to this Scheme which NCLT or any authorities under law may deem fit to approve of or may impose and which the Board of Directors of the Transferor Companies and the Transferee Company may in their discretion accept, or such modification(s) or addition(s) as the Board of Directors of the Transferor Companies and the Transferee Company or as the case may be, their respective Delegate may deem fit, or required for the purpose of resolving any doubts or difficulties that may arise in carrying out this Scheme.
- 17.2. The Transferor Companies and the Transferee Company by their respective Boards of Directors or Delegates are authorised to do and execute all acts, deeds, matters and things necessary for bringing this Scheme into effect or review the position relating to the satisfaction of the conditions of this Scheme and if necessary, waive any of such conditions (to the extent permissible under law) for bringing this Scheme into effect, and/or give such consents as may be required in terms of this Scheme. In the event that any conditions are imposed by NCLT or any Governmental Authorities, which the Board of Directors of the Transferor Companies or the Transferee Company find unacceptable

for any reason, then the Transferor Companies and the Transferee Company shall be at liberty to withdraw the Scheme.

- 17.3. For the purpose of giving effect to this Scheme or to any modification(s) thereof or addition(s) thereto, the Delegates (acting jointly) of the Transferor Companies and Transferee Company may give and are authorised to determine and give all such directions as are necessary for settling or removing any question of doubt or difficulty that may arise under this Scheme or in regard to the meaning or interpretation of any provision of this Scheme or implementation thereof or in any matter whatsoever connected therewith (including any question or difficulty arising in connection with any deceased or insolvent shareholders or depositors, if any of the Transferor Companies) or to review the position relating to the satisfaction of various conditions of this Scheme and if necessary, to waive any such conditions (to the extent permissible in law) and such determination or directions or waiver, as the case may be, shall be binding on all parties, in the same manner as if the same were specifically incorporated in this Scheme. For the avoidance of doubt, it is clarified that where this Scheme requires the approval of the Board of Directors of the Transferor Companies or the Transferee Company to be obtained for any matter, the same may be given through their Delegates.

18. FILING OF APPLICATIONS

The Transferor Companies and the Transferee Company shall use their best efforts to make and file all applications and petitions under Sections 230 to 232 and other applicable provisions of the Act, before the respective NCLT having jurisdiction for sanction of this Scheme under the provisions of law and shall apply for such approvals as may be required under law.

19. APPROVALS

The Transferee Company shall be entitled, pending the sanction of the Scheme, to apply to any Governmental Authority, if required, under any law for such consents and approvals which the Transferee Company may require to own the Undertakings and to carry on the business of the Transferor Companies.

20. SCHEME CONDITIONAL UPON SANCTIONS, ETC.

This Scheme is conditional upon and subject to:

- 20.1. The Scheme being approved by the requisite majority of the respective classes of shareholders and/or creditors, as applicable, of the Transferor Companies and of the Transferee Company as required under the Act applicable, and the requisite order of being obtained or dispensation having been received from the NCLT in relation to obtaining such consent from the shareholders and/or creditors, as applicable;

- 20.2. Such other approvals and sanctions including sanction of any statutory authority, as may be required by law or contract in respect of the Scheme;
- 20.3. The draft Scheme being filed with the Stock exchange for disclosure purposes. Para 7 of SEBI Circular no. CFD/DIL3/CIR/2017/21 dated March 10, 2017 provide that the company shall file the draft scheme with Stock Exchanges for the purpose of disclosures;
- 20.4. The NCLT having accorded sanction to the Scheme and if any modifications have been prescribed the same being acceptable to the Transferor Companies and the Transferee Company; and
- 20.5. Such certified / authenticated copy of the order of the NCLT being filed with the Registrar of Companies.

21. EFFECT OF NON-RECEIPT OF APPROVALS/SANCTIONS

- 21.1. In case the Scheme is not approved by the NCLT or any of the approvals or conditions enumerated in the Scheme have not been obtained or complied with, or for any other reason, if this Scheme cannot be implemented, then the Board of directors of the Transferor Companies and the Transferee Company shall mutually waive such conditions as they consider appropriate to give effect, as far as possible, to this Scheme and failing such mutual agreement, the Scheme shall become null and void and each party shall bear their respective costs, charges and expenses in connection with this Scheme.
- 21.2. If any part of this Scheme hereof is invalid, held illegal by any court and/or tribunal and/or statutory authority of competent jurisdiction, or unenforceable under any present or future laws, then it is the intention of the parties that such part shall be severable from the remainder of the Scheme and the Scheme shall not be affected thereby, unless the deletion of such part shall cause this Scheme to become materially adverse to any party, in which case, the parties shall attempt to bring about a modification in the Scheme, as will best preserve for the parties the benefits and obligations of the Scheme, including but not limited to such part.

22. PROCEDURAL FORMALITIES POST SANCTION OF THE SCHEME – BUSINESS CONTINUITY

- 22.1. The amalgamated/Transferee Company shall, at any time after the coming into effect of this Scheme in accordance with the provisions hereof, if so required under any law or otherwise, execute deeds of confirmation or novation or other writings or arrangements with any party to any contract or arrangement in relation to which the amalgamating/Transferor Companies has been a party, in order to give formal effect to the above provisions. The amalgamated/ Transferee Company shall, under the provisions of this Scheme, be deemed to be authorized as a constituted attorney to execute any such deeds, writings, documents, receipts and discharges on behalf of the Transferor Companies and to carry out or perform all such formalities or compliances

referred to in this Scheme on the part of and for and behalf of the Transferor Companies as if the Transferor Companies has not been dissolved without being wound-up.

- 22.2. Upon the Scheme becoming effective, for statistical purposes only and without any separate deed, instrument or writing, the Transferor Companies and/or the amalgamated/Transferee Company shall, if required, simultaneously with the amendment in the register of charges and file particulars of the modified charge with the concerned Registrar of Companies. Any documentation subsequently entered into with the term lenders or the working capital lenders of the Transferor Companies and the amalgamated/Transferee Company, shall be for the sake of convenience and record only and to reflect the changes in the security pursuant to the Scheme and there shall be no break in the continuity of such charge and the same shall relate back to the date of its creation thereof in the Transferor Companies.
- 22.3. Upon the Scheme becoming effective, all statutory permissions, licenses, approvals, consents, privileges, benefits and benefits of filings and all other incorporeal rights emanating from such licenses (together the "Licenses", for the purpose of this Clause) relating to the Transferor Companies, shall stand transferred to and vested in the amalgamated/Transferee Company without any further act, instrument or deed, as more particularly provided hereinabove. Notwithstanding such transfer /vesting of the Licenses, if any application is required for the statistical record of the statutory authorities to implement the transfer and vesting of the Licenses, as provided hereinabove, the amalgamated/Transferee Company shall facilitate the statutory authorities by filing such applications, which shall be granted /approved in favour of the amalgamated/Transferee Company based on the sanction order of the Scheme by the NCLT.
- 22.4. Upon the Scheme becoming effective, the Transferee Company is expressly entitled and authorized under the Scheme by the Transferor Companies to revise its direct or indirect tax returns and related withholding certificates and shall be entitled to claim refund, advance tax credits including MAT credit, CENVAT credit, pertaining to the Transferor Companies, if any.
- 22.5. From the Effective Date, all bank accounts of the Transferor Companies shall be permitted to be continued with the same balances as of the Effective Date in the name of the amalgamated /Transferee Company and for statistical record the amalgamated/Transferee Company shall be permitted to file names and particulars of the new authorised signatories for withdrawals and/ or deposits/ credits in such bank accounts and the relevant bank accounts shall be reconstituted accordingly.
- 22.6. The powers and authorization granted to and to be exercised by the amalgamated/Transferee Company in terms of Clauses 22.1 to 22.5 herein are with the aim and intent that the business and operations relating to the Undertaking transferred

herein of the Transferor Companies even after the Effective Date are transitioned and continue on a "Going Concern Basis" without any interruption or break in continuity.

23. SAVING OF CONCLUDED TRANSACTIONS

Subject to the terms of this Scheme, the transfer and vesting of the Undertaking of the Transferor Companies under Clause 4 of this Scheme shall not affect any transactions or proceedings already concluded by the Transferor Companies on or before the Appointed Date or concluded after the Appointed Date till the Effective Date, to the end and intent that the Transferee Company accepts and adopts all acts, deeds and things made, done and executed by the Transferor Companies as acts, deeds and things made, done and executed by or on behalf of the Transferee Company.

24. COSTS, CHARGES AND EXPENSES

All costs, charges and expenses of or payable by each of the Transferor Companies and the Transferee Company in relation to or in connection with this Scheme and incidental to the completion of the amalgamation of the Transferor Companies and the Transferee Company in pursuance of this on the Order of the NCLT, if any, shall be

24.1. borne and paid by the Transferor Companies till the Effective Date; and

24.2. borne and paid by the Transferee Company after the Effective Date.

.....